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Abstract
Non-toxic goitre (NTG) is one of the commonest thyroid disorders world 
wide. This study followed, clinically and using ultrasonography, a small 
group of patients with NTG receiving a 6 month treatment course of 
sodium thyroxine and observed whether thyroxine would decrease 
significantly the thyroid volume or palpable size of the thyroid gland. 
This was not shown to be the case and no change could be demonstrated. 
Thyroid growth immunoglobulins (TGI) have been implicated in the 
development of NTG. The presence of TGI in the IgG fi"om the subject 
groups was determined by their ability to stimulate proliferation in the 
Fischer rat thyroid cell line (FRTL5). Detection of proliferation in the 
FRTL5 cells was measured using 3 different methods.
The first was colourimetric and used the dye 3-[4,5-dimethythiazol-2-yl]- 
2,5-diphenyltetrazolium bromide (MTT), with which a significant 
increase in TGI was detected in the Multiple Sclerosis (MS) group when 
compared with the normal control (NC) and goitre groups. The second 
method used the incorporation, of ^H-thymidine into FRTL5 cells, this 
revealed a significant statistical decrease in the post treatment goitre 
group when compared to the pre treatment goitre group. The final 
method, a commercially available kit, employed the incorporation of 5- 
bromo-2’-deoxyuridine (BrdU) into FRTL5 cells and showed a 
significant reduction in the presence of TGI in the MS group when 
compared to the NC group. The studyT also revealed poor correlation
between the MTT and H-thymidine methods. The significance of these 
results is discussed.
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Chapter One General Introduction
1.1 The Thyroid Gland
1.1.1 Thyroid Development: Embryonic, Anatomical and 
Functional (McDougall 1992a).
In the embryo the thyroid develops from the foregut and descends by a 
circuitous route to its normal cervical position. The first evidence of its 
presence occurs at around four weeks gestation as an évagination 
between the first and second pharyngeal pouches. This évagination 
lengthens to form a tube and descends inferiorly and anteriorly, passing 
the hyoid bone anteriorly. It loops round and behind the hyoid before 
continuing its descent in the neck. The lateral lobes form from two 
lateral buds, these fuse with the ultimobranchial body that supplies cells 
which become the parafollicular cells. The pathway from pharynx to 
anterior neck is marked by the thyroglossal duct. The tubular structure is 
lost and by the sixth week atrophies.
Early growth and development of the thyroid do not seem to be thyroid 
stimulating hormone (TSH) dependent as the pituitary does not appear to 
synthesize and secrete TSH until week 10-12.
Thyroprotein appears as early as 29 days post conception and predates the 
capacity to concentrate iodide. At week 11 iodide can be concentrated by 
the thyroid and T4 synthesized. Thyroid hormones condition late phase 
skeletal maturation and influence late pre-natal lung maturation. They
are required for normal development of brain and intellect (Larsen and 
Ingbar 1992a).
Foetal thyroid tissue grows roughly in parallel with body weight, 
weighing approximately 0.2 g .at 20 - 25 weeks (Spencer and Banever 
1970). Immediately after birth there is a sharp rise in TSH. This is 
thought to provide heat for the new-born.
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Figure 1.1 Diagram of The Thyroid (in relation to the trachea, 
neck muscles and manubrium from McDougall 
1992).
1.1.2 Physiology of the Thyroid Gland (Larsen and Ingbar 1992a)
The thyroid gland is located anteriorly in the neck below the thyroid 
cartilage. It weighs approximately 20 grammes in the normal healthy 
adult and has huge potential for growth^ some goitres can weigh hundreds
of grammes. The thyroid gland is bilobed, resembling two halves of a 
large plum, connected by the isthmus and situated on either side of the 
trachea (Figure 1.1) Each lobe measures approximately 2.0 - 2.5 x 2.0 x 
4.0 mm, but the right lobe tends to be larger and even more highly 
vascularised than the left. The thyroid filters 4.0 - 6.0 mls/min/g of 
blood. The kidney by comparison filters 3.0 mls/min/g. Each lobe is 
fixed by connective tissue to the lateral aspects of the trachea, the upper 
margin of the isthmus lying just below the cricoid cartilage. Thyroid 
tissue is composed of thyroid follicular cells, the thyrocytes, which make 
up 70 % of the total cells. The remainder is comprised of some 20 % 
endothelial cells and 10 % fibroblasts (Dumont et al. 1991). These are 
arranged in spherical structures called follicles and are supported by 
mesenchymal tissue and cells (Klinck et al. 1970). Figure 1.2 shows the 
follicle and follicular cell structure.
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Figure 1.2 Diagram showing the follicle and follicular cell from 
McDougall (1992).
Physiological enlargement of the thyroid occurs at puberty, (especially in 
females), during pregnancy and at the menopause and in some normal 
females it is visible to the naked eye.
The parathyroid glands are situated on or beneath the posterior surface of 
the thyroid lobes. Calcitonin secreting parafollicular cells are located at 
the periphery of the follicles.
1.1.3 Endocrine Function
As an endocrine gland the thyroid produces and secretes two 
physiologically important hormones into the blood stream, thyroxine (T4) 
and tri-iodothyronine (T3). Both are stored in the gland follicles loosely 
coupled to thyroglobulin. Release is regulated by TSH from the pituitary 
gland. Dietary iodine, is preferentially extracted from the blood stream 
by thyroid follicular cells, the rate of which is also regulated by TSH 
secretion (McDougall 1992b). It is transported across a basal membrane 
into the thyroid cell in a process involving active transport which 
concentrates iodide against a chemical and electrical gradient (Wolff 
1964). There is accumulation within the cell and movement across it to 
the apical membrane. It is thought that the iodide is oxidised at or near 
the apical membrane by peroxidase in the presence of hydrogen peroxide 
(Strum and Kamovsky 1971). It then couples with the tyrosine residues 
of thyroglobulin forming mono-iodotyrosine (MIT) and di-iodotyrosine 
(DIT). One molecule each of MIT and DIT combine to form T3, T4 is 
formed from the coupling of 2 DIT molecules. Hydrolysis of 
thyroglobulin results in the release of T3, T4, MTT, DIT and amino acids 
(Dunn and Dunn 1982). Microsomal iodotyrosine dehalogenase de- 
iodinates the MIT and DIT and the iodide is then reused in the follicle 
(McDougall 1992b).
In the circulation the vast majority of T4 and T3 are bound to thyroxine 
binding globulin, thyroxine binding prealbumin and albumin which 
renders them metabolically inactive (Oppenheimer et al. 1968, Robins et
al. 1978). Only about 0.4 % of T3 and 0.04 % of T4 circulate in the 
unbound (free) state. In peripheral tissues free T3 exerts its influence 
instantly on all body cells. T4 requires conversion to T3 and is therefore 
slower acting (Braverman et al. 1970, Sterling et al. 1970, Balsam and 
Ingbar 1979). These thyroid hormones regulate oxygen consumption of 
all body cells and tissues and are essential for normal growth and 
development, both physical and mental (Felig et al. 1987). Thyroxine is 
more abundant than T3, but T3 is more important at the cellular level 
(Schwartz et al. 1971).
TSH is a glycoprotein, with a molecular weight of 28,000 daltons and is 
synthesised by the thyrotropes of the anterior pituitary (Pierce 1971, 
Pierce and Parsons 1981). It has a half life in the circulation of 
approximately 1 hour and is metabolised mainly in the liver and kidneys 
(McDougall 1992b). T3 and T4 receptors can be found on the 
thyrotrophes of the anterior pituitary and have around 1 0 - 2 0  times 
greater affinity for T3 than T4 (De Groot et al. 1989). TSH has a distinct 
circadian rhythm, it is secreted episodically and in individually variable 
patterns (Week and Gundersen 1978). It also shows a diurnal variation, 
peaking at around midnight to 3 or 4 am with a nadir at about 11 am to 
12 noon. The secretion of TSH is pulsatile with peaks every 10 minutes 
(Greenspan et al. 1986).
The synthesis and secretion of TSH is stimulated by thyrotrophin 
releasing hormone (TRH) from the hypothalamus in response to low 
levels of circulating thyroid hormones (Burgus et al. 1970, Patel et al. 
1972, Sterling and Lazarus 1977). Elevated levels of T3 and T4 in the
blood suppress the production of TSH by negative feedback to both the 
hypothalamus and the pituitary (figure 1.3). The thyroid is also capable 
of self regulation which is thought to involve the homeostasis of stored 
thyroid hormone, although this is less important than the TSH control 
mechanism (Ingbar 1972). The hypothalamus is also sensitive to less 
well defined influences i.e. weather, seasons, temperature and 
temperament.
PositiveTRH
Negative
PositiveTSH
Thyroid
Pituitary
Hypothalamus
Higher centres
T. T3 Tissues
Figure 13 Simplified diagram of the control of thyroid function 
fi-om McDougall (1992).
1.2 Goitre Development
1.2.1 Aetiological Factors
There are many causes of thyroid gland enlargement (goitre) including:-
Inflammation
Autoimmunity
Neoplastic disease
Iodine deficiency
Inherited and acquired dyshormonogenesis
Goitrogens
Puberty
Pregnancy
Smoking (Ericsson and Lindgarde 1991)
In 1928 Chesney et al. provided the first evidence that foodstuffs 
contained goitrogenic substances by demonstrating the development of 
goitres in rabbits fed on cabbage (genus brassica). Since then other 
vegetables have been found to possess goitrogenic properties. Over the 
last 20 years it has been shown that thiocyanate and isothiocyanate in 
these cruciferae were the actual goitrogens (Podoba et al. 1973, Ermans 
et al. 1980, Delange and Ahluwalia 1983, Eltom et al. 1984, Gaitan
1989). Thiocyanate acts by blocking the iodide pump. This is the 
mechanism which concentrates serum iodide 25 - 50 times (Gmelin and 
Virtanen 1960).
Although it is now a rare event, sporadic goitres have developed as a 
result of dietary idiosyncrasy or medication (Vought et al. 1972, 
Braverman 1986). Iodine was sometimes used to treat various 
pathologies such as tuberculosis, leprosy, syphilitic and mycotic lesions 
where the immune mechanism is known to play a major role (Braverman
1986). The mechanism by which iodine does this is unknown, however it 
has been proposed that it acts by increasing the immune response (Manari 
and Venturi 1986). Potassium iodide is contained in some expectorants. 
Prescription of iodopyrine for asthma has resulted in as many as 30 % of 
recipients developing goitres. Other potent medicinal sources include 
amiodarone, multivitamins and some dyes used to colour pills and 
foodstuffs (Braverman 1986). In Japan endemic goitre affects 10 % of 
the coastal population of Hokkaido due to high consumption of seaweed 
(Gaitan 1988). Iodine administration during pregnancy may result in an 
infant with goitre, as can administration of radiographic contrast media. 
Lithium carbonate used in the treatment of manic depressive psychosis, 
has also been well described in goitre development (Schou et al. 1968). 
In the rat it has been shown that lithium acts by blocking the resorption of 
thyroglobulin (Leppuluoto et al. 1973). Soya bean factors have a similar 
mode of action (Van Wyk et al. 1959). Soya bean formula, prior to being 
enriched with iodine, has lead to goitre in infants by enhancing faecal 
loss of hormone. The pesticide dithiocarbamate and propylenethiourea, 
its metabolite and degradation product, have been shown to be both 
teratogenic and goitrogenic in the rat (Vitari et al. 1985), but as yet there 
has been no human evidence of this.
1.3 Non-Toxic Goitre
Goitres, from the Latin, guttur, meaning throat, were reputedly known in 
China as early as 2700 BC. Amongst other Italians of the Renaissance 
period, Leonardo da Vinci (1452-1519), described the thyroid gland. In 
1619 Fabricius ab Acquapendente (1537-1634) recognised that goitres 
arose from the thyroid. In 1776 Albrecht von Haller (1708-1777) of 
Berne described the thyroid as a ductless gland.
1.3.1 Definition of Non-Toxic Goitre
Non-toxic goitres (NTG) are also known as simple, sporadic or euthyroid 
goitre. The most widely adopted criteria for goitre definition are those of 
Perez et al. (1960). Non-toxic goitre is incapable of precise definition. 
The term is used exclusively to describe abnormal thyroid enlargement 
not associated with hyper or hypothyroidism and not as a result of an 
inflammatory or neoplastic process (Larsen and Ingbar 1992c). The 
modified WHO definition is that of a slowly developing diffuse or 
nodular enlargement of the thyroid gland, resulting from excessive 
replication of epithelial cells with subsequent generation of new follicles 
of widely differing structure and fimction (Studer and Rameli 1982).
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1.3.2 Clinical Aspects
Simple goitres are not painful, rarely interfere with swallowing or 
breathing and are quite often discovered accidentally. They can be 
disfiguring when multinodular and haemorrhage into them can cause pain 
and swelling. Clothing around the neck can feel tight and rarely 
compression symptoms may affect the trachea, oesophagus and laryngeal 
nerves. As a result of thyroid enlargement there can be dysphagia, 
choking, inspiratory stridor and venous engorgement.
1.3.3 Diagnosis
It is important to investigate any enlargement of the thyroid gland if only 
to allay patient fears. On examination the normal thyroid gland can be 
felt to be smooth and firm. A thyroid gland whose lateral lobes have a 
volume greater than the phalanges of the thumb of the examiner is said to 
be goitrous (Querido et al. 1974).
In NTG serum T3, T4 and TSH are all within the normal range, (for our 
lab the reference ranges are T3; 0.9 - 2.8 nmol/L, T4; 55 - 144 nmol/L, 
and TSH; <5.0 mU/L). This ultrasensitive TSH assay can detect levels of 
TSH down to 0.05 mU/L. The T3/T4 ratio is often increased perhaps 
reflecting defective iodination of thyroglobulin (Ermans 1969, Rapoport 
et al. 1972, Studer et al. 1974). Serum thyroglobulin is increased 
(Pezzino et al. 1978). Radiolabelled iodine uptake is increased possibly 
due to mild iodine deficiency and a biosynthetic defect. In long-standing
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multinodular goitre (MNG) functional autonomy may be reflected by a 
decreased or absent response to TRH. It has not been possible to 
demonstrate any correlation between TSH levels and goitre development 
(Delange et al. 1971). The factors that lead to goitrous hypothyroidism 
can also lead to NTG, hence the tendency to hypothyroidism. With time 
NTG’s may become multinodular displaying varying degrees of 
autonomy, ranging from clinically euthyroid to thyrotoxic (Studer 1982). 
Diffuse NTG can resemble Graves’ or Hashimoto’s disease. If the 
Graves’ disease is not actively toxic and there is no ocular involvement 
differentiation is difficult, but the presence of autoantibodies to the 
thyrotropin receptor is diagnostic of autoimmune disease, being present 
in ~80 % of patients with active Graves’ disease (Larsen and Ingbar 
1992b). The thyroid hyperfunction seen in Graves’ disease results from 
the binding of these abnormal immunoglobulins to the thyroid plasma 
membrane, where they activate adenylate cyclase and induce thyroid 
growth. This results in an increase in vascularity and rate of hormone 
production and secretion. The immunoglobulins have not yet been 
differentiated by chemical or immunological means and demonstration of 
their presence is based on assessing the capacity of IgG to stimulate 
adenylate cyclase or increase the concentration of cyclic AMP in human 
thyroid slices or membrane preparations, they are referred to as thyroid 
stimulatory immunoglobulin (TSI) (Smith et al. 1988). In Hashimoto’s 
thyroiditis, where the gland is usually more firm and irregular, an 
increase in antithyroid antibodies distinguishes it from NTG. Carcinoma 
can also resemble NTG and is diagnosed by biopsy (fine needle).
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1.3.4 Incidence and Epidemiology
In the United Kingdom distribution of thyroid size in the general 
population is positively skewed with more high values (Koutras 1972). 
Solitary thyroid nodules can be palpated in around 4 - 7 % of the general 
population (Van Herle et al. 1982, Christensen et al. 1984, Rojeski and 
Gharib 1985, Gharib et al. 1987). Post mortem and ultrasound studies 
have shown them in about 50 % of individuals aged up to 50 (Horlocker 
et al. 1986, Burrow 1989). Goitre prevalence of >10 % is usually taken 
as the demarcation line between areas of endemic iodine deficiency and 
sporadic goitre (Lamberg 1991). Endemic goitre is not a problem in the 
United Kingdom.
In sporadic goitre iodine intake and autoimmune thyroiditis are the major 
determinants with environmental factors and heredity occasionally 
contributing (Podoba et al. 1973, Delange 1974). Goitres can develop at 
pregnancy or puberty, but the pathogenesis of these events is unknown 
and the goitre may regress or remain. There is an increased fi*equency of 
NTG in menopausal women, with a female/male ratio of 4:1 (Kilpatrick 
et al. 1963). This increase in prevalence is also augmented with age 
(Rojeski and Gharib 1985).
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1.4 Aetiology of Non-T oxic Goitre
Non-toxic goitre is thyroid enlargement with no pathological explanation, 
no detectable disturbance of thyroid function and no identifiable extrinsic 
goitrogenic factor. There is no concrete evidence to suggest that simple 
goitre is related to hereditary factors nor to a defect in thyroid hormone 
biosynthesis, which could be at any point from iodine trapping to the 
release of iodothyronines.
1.4.1 The Role of TSH
The major element controlling thyroid growth in vivo is TSH (Dumont 
1971). The traditional theory suggests that NTG develops in response to 
any of several factors that impair thyroid efficiency in the manufacture of 
adequate quantities of hormones. When this happens hypersecretion of 
TSH leads to stimulation of thyroid growth and increase in activity of the 
processes concerned with hormone biosynthesis that are capable of 
responding. As a result of increase in thyroid mass and unit functional 
activity a normal rate of hormone secretion is restored and the patient 
rendered eumetabolic but goitrous.
The concept that it may be an intrinsic inborn abnormality is not 
supported by the finding that TSH is seldom elevated in patients with 
non-toxic goitre (Toft et al. 1976). In the non-iodine deficient Whickham 
study, TSH and mean thyroid hormone levels were not found to be 
significantly different between goitrous and non-goitrous members of the
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community (Tunbridge et al. 1977).
These findings may be explained thus; in hypophysectomysed rats, the 
response of thyroid weight to standard doses of TSH is augmented by 
previous thyroid iodine depletion (Brady 1968). Hence any factor 
impairing normal iodine usage may lead to gradual development of goitre 
in response to normal TSH concentrations, as an increase in TSH 
concentration may be small and significant but not detectable. Also the 
original goitrogenic stimulus may no longer be present at the time of 
study. The residual normal TSH concentration maintains but has not 
initiated the goitre. As previously stated relative iodine deficiency may 
account for some goitres, with goitrous individuals having a lower iodine 
uptake than non-goitrous controls (Alexander et al. 1962).
The following are common features of NTG which are not attributable to 
iodine deficiency (Studer and Ramelli 1982).
1. There is structural and functional heterogeneity between single 
follicles or between different regions of a goitre.
2. Goitres develop in spite of abundant supplies of iodine.
3. Development of single and multiple nodules.
4. Pathogenesis of hot and cold follicles.
5. Pathogenesis of hyperthyroidism in simple goitre.
1.4.2 Iodine Deficiency
Iodine deficiency although implicated has never received the attention 
that TSH has in sporadic goitre development even though it does so
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possibly through an autoregulatory mechanism (Gartner and Pickardt
1990).
The main physiologic regulators of the thyroid gland are TSH and iodide. 
Doubts have been expressed regarding the role of TSH in goitre 
development (Garter and Pickardt 1990, Edmonds 1992). There is no 
doubt that fimctions such as iodine organification, thyroglobulin and 
thyroid hormone synthesis and secretion are controlled by TSH. It would 
be expected but there is no increase in TSH in sporadic goitre (Gutekunst 
et al. 1986).
The claim that the iodine deficient thyroid is more sensitive to TSH is 
true for function and hypertrophy (pathological enlargement of cells) and 
is easily demonstrated but has not been demonstrated for hyperplasia 
(increase in total cell number) argues Gartner (1994). The experiments 
carried out by Brady (1968) on hypophysectomysed rats have also been 
criticised. The rats used were either given a low iodine diet or fed 
goitrogens, these experiments were carried out over only 12 days during 
which time it would be impossible to demonstrate an increase in the total 
cell number, instead it is claimed that it is the enlargement of cells which 
is induced by short term TSH stimulation (Gartner 1994). In support of 
this is the fact that cell divisions are very rare in goitre only 3 % of cells 
and <1 % of normal thyroid cells are in mitosis (Dumont et al. 1991). In 
vitro intact isolated thyroid follicles with preserved polarity, 
thyroglobulin content, cell to cell contact and biological extracellular 
matrix have no spontaneous growth behaviour in the presence of low 
concentrations of foetal calf serum (PCS). They primarily organify
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iodine and secrete thyroid hormones when stimulated with TSH and only 
proliferate when iodine content of the follicle decreases. This is because 
of the lack of iodine in the culture medium, however if adequate iodine is 
available there is no increase in cell proliferation even in the presence of 
high TSH concentrations (Gartner 1992).
In contrast thyroid epithelial cells when dispersed onto plates grow to 
confluence in the presence of PCS most are in mitosis and can be 
modulated by growth factors, TSH and CAMP, this cannot be 
demonstrated in vivo.
1.4.3 Thyroid Growth Immunoglobulins (TGI)
The involvement of a TGI, specific for thyroid cell growth, in the 
pathogenesis of NTG would certainly implicate autoimmunity and would 
provide an attractive explanation for the phenomenon of NTG (Drexhage 
et al. 1980). Unlike Graves’ IgG this TGI does not act through adenylate 
cyclase nor specifically bind to the TSH receptor (Drexhage et al. 1983). 
The existence of such would account for (Studer and Ramelli 1982):-
1) the female prevalence
2) increase in familial incidence
3) occurrence of goitres in non-iodine deficient areas
4) explain continuous growth despite suppression with thyroxine therapy
5) explain the colloid rich structure.
TGI may account for different thyroid sizes in Graves’ patients and 
explain atrophy of the thyroid in non-goitrous hypothyroidism. Patients
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in whom autoimmune non-toxic goitre is thought most likely are those in 
whom other autoimmune phenomena are present in themselves or their 
families, e.g. pernicious anaemia, Addison’s disease, diabetes mellitus, 
myasthenia gravis, or goitres returning after sub-total post thyroidectomy, 
although more evidence is required to support this finding (Valente et al. 
1983a).
Evidence as to the immunological nature of the thyroid growth stimulator 
was shown by Van der Gaag et al. in 1985 who demonstrated that the 
growth response seen in a group with simple goitre could be abolished by 
pre-treating the immunoglobulin (Ig) with antihuman Ig, confirming the 
immunoglobulin nature of the growth stimulator.
TGI have been detected by indices of growth i.e. labelled thymidine 
incorporation, increase in DNA content and increase in cell number in 
cultured thyroid cell systems (Drexhage et al. 1980, Smyth et al. 1982, 
Wilders-Trushing et al. 1990).
Neither TSH nor TGI explains why long standing NTG becomes nodular. 
NTG is characterised by anatomical and functional heterogeneity and 
functional autonomy, presumed to be due to hyperstimulation by TSH or 
fi’om repeated cycles of hyperstimulation and involution thus leading to 
areas of hyperplasia (autonomy and atrophy). After a time autonomous 
tissue is sufficient to suppress TSH secretion giving a subnormal 
response to TRH administration.
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1.4.4 Growth Factors
There is evidence to indicate that other paracrine and autocrine growth 
factors, such as Insulin like growth factor 1 (IGFl) and Insulin like 
growth factor 2 (IGF2), may also be involved in modulating thyroid 
growth (Westermark et al. 1983, Tramontane et al. 1986, Shin-Ichiro et 
al. 1990). The local hormone transforming growth factor p (TGFp) has 
been shown to inhibit thyroid growth (Grubech-Loebenstein et al. 1989, 
Bidey 1990). Subconfluent human thyroid cells isolated from non-toxic 
thyroid tissue obtained at surgery responded to human epidermal growth 
factor (EGF) in a dose dependant manner with an increase in 
incorporation of tritiated thymidine (^H-thymidine), ranging from 25 - 60 
%. There was also inhibition of T3 secretion of between 20 and 45 % 
(Ollis et al. 1985).
In more recent studies IGFl, EGF, TGF (a and P) and pFGF have been 
studied extensively (Dumont et al. 1991, Gartner 1992). It is claimed that 
release of these growth factors is under the control of iodine 
supplementation of thyroid cells along with TSH. Changes in the iodine 
content of the follicle decreases the paracrine release of TGFp and pFGF 
responsible for matrix formation and endothelial cell proliferation that 
are mainly released under the influence of EGF the most potent (Gartner 
1992). In contrast high iodine content of thyroid follicles decreases this 
paracrine release of TGFp and PFGF and the growth response to EGF. 
When stimulated by TSH IGFl is released but only when the iodine
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content of the follicles are low. When the iodine content is normal TSH 
stimulation leads only to thyroid hormone secretion and not to the release 
of IGFl or the expression of IGFl mRNA. Blocking the IGFl receptor 
with an antibody specific to it results in the abolishment of any growth 
effect to TSH on thyroid epithelial cells (Rafferzeder et al. 1993). This 
would imply that TSH is only indirectly involved in thyroid cell 
proliferation and strongly dependent on iodine, although TSH is able to 
modify iodine intake.
In rat thyroids it was first demonstrated that intense replication of stromal 
cells occurred simultaneously with the multiplication of follicular 
epithelia (Santler 1957). Since then it has been hypothesised that stromal 
cells play an actual role in thyroid growth. The stroma is a minor 
component of the thyroid gland in terms of volume with little importance 
attached to it. A thin sheath of fibroblasts and capillary network surround 
each thyroid follicle, it is therefore evident that epithelial and stromal 
growth must be closely co-ordinated by humoral communication 
(Dumont et al. 1991). Growth response to TSH, in vitro, of isolated 
normal thyroid follicular cells was shown to be IGFl dependent (Smith 
1988, Williams et al. 1988). As IGFl is not normally an autocrine 
product of thyroid epithelium, the IGFl must therefore be fi'om another 
source. Fibroblasts have been shown to produce IGFl (Gartner et al.
1987), suggesting that epithelial and stromal cells could be 
interdependent for thyroid growth control.
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1.4.5 Autoimmune Associations
Multinodular goitres have been associated with autoimmune thyroiditis, 
but there is a poor association between simple goitre and thyroid 
autoantibodies. Even so several workers support the theory that most 
sporadic non-toxic goitres involve disorders of immune regulation and 
self-recognition, with disturbances of T suppressor cell function (Von 
Blomberg and Kokje 1984, Van der Gaag et al. 1985).
The following evidence indicates a link with autoimmune disease.
1. Autonomous thyroid growth; autonomy has been shown by the fact 
that thyroid growth continues in iodine deficient and non-deficient 
goitres and also with TSH suppression (De Smet 1960, Peter et al. 
1985 and 1986, Studer et al. 1989).
2. Goitre regrowth post thyroidectomy; experiments on mice with 
inherited absence of TSH showed that the remaining lobe still 
hypertrophied after hemi-thyroidectomy (Lewinski et al. 1983). The 
very variable growth potential of individual thyroid cells together with 
local and systemic growth factors could itself be important in the 
evolution of sporadic goitres (Studer et al. 1989).
3. The purported existence of thyroid growth immunoglobulins discussed 
in 1.4.3.
It has been suggested that some varieties of NTG may be precursors to 
Graves’ disease. This is due to the observation that after long term 
follow up some cases of non-toxic adolescent goitre have resulted in a 
high fi-equency of toxic goitre, even when suppressive doses of thyroid
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hormone were being administered. In NTG iodine deficiency is 
obviously more important than genetic factors. A study on twins by 
Phillips (1994) demonstrated that heredity does play a role in the genesis 
of NTG. Confirmation of this has also come fi'om studies on the increase 
in goitre fi-equency among children with two goitrous parents, compared 
to those with one such parent, with those neither of whose parents had a 
goitre showing the lowest fi-equency of all (Freidman and Fialkow 1983).
1.4.6 Clonal Heterogeneity
Studer proposed his theory of NTG development in 1982. This concept 
is of clonal heterogeneity and results fi-om clonal differences among those 
cells that give rise to thyroid follicles some being more and some less 
responsive to external stimulation by TSH and some being autonomous at 
the outset. Individual responses to TSH might also vary firom clone to 
clone with respect to iodine accumulation, exocytosis of thyroglobulin or 
resorption of colloid. This concept implies that the basis of anatomical 
and functional heterogeneity exists within the thyroid at the outset of the 
disease and is exaggerated by prolonged stimulation.
1.4.6.1 Goitre Development Microscopically
The basic process in every simple goitre is the increase in epithelial cell 
mass and the generation of new follicles (Gerber et al. 1981). 
Histologically the predominant cells are follicular epithelia, although no
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single type of follicle characterises simple goitre. Diseased glands 
consist of endless varieties and shapes of follicles (Studer et al. 1978, 
Milone and Studer 1980).
In rat models three phases of thyroid growth have been shown due to 
sustained elevation of serum TSH induced by goitrogen administration. 
Firstly there is a phase of rapid growth lasting 1 -2  months, followed by 
a plateau period of 3 - 6 months where there is little increase in weight 
and the third is the appearance of multiple follicular thyroid tumours 
(Purves and Greisbach 1946, Philp et al. 1969). This limitation of the 
initial growth response occurs despite undiminished TSH stimulation. 
This results in the maintenance of functional activity but loss of 
proliferative responses (Wynford-Thomas et al. 1982). This altered 
response is thought to be mediated by an intracellular change in the 
follicular cell either at the receptor or post-receptor level rather than by a 
chalone (Stringer et al. 1985). (A chalone is an internal secretion of an 
inhibitory nature opposing the action of hormones (Chambers Science 
and Technology Dictionary 1984).
Two factors are pre-requisite to the development of NTG:-
1) Low intensity goitrogenic stimulus. This was used to induce simple 
goitres in experimental animals (Olen 1969, Strum and Kamovsky
1971). Heavy goitrogenic stimulation leads to the difhise hypertrophy 
seen in Graves’ disease (Marine 1928, Taylor 1953).
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2) The second factor is time. It has been proposed that the typical 
microscopic, macroscopic and functional heterogeneity seen in NTG 
only develops if the mild goitrogen acts intermittently (Gerber et al. 
1981) and is present over a long period of time (De Smet 1960).
1.4.6.2 Goitre Development Macroscopically
Long-standing heterogeneous goitres can be identified by gross 
differences in structure and natural colour within and between different 
nodules, nodular growth of the parenchyma, strands of connective tissue, 
along with fresh haemorrhagic necroses and scarred calcified areas of 
necrosis (Taylor 1953, Correa 1980). The mechanism is probably similar 
to that causing tissue necrosis in tumours i.e. as newly growing tissue 
requires new capillary networks, failure to meet the ever increasing 
demand for blood supply, to the growing number of follicles, is likely to 
cause tissue death (Studer and Ramelli 1982).
NTG is initially diffuse and later multinodular. There is diffuse 
hypertrophy and hyperplasia of the epithelium lining follicles, the cells 
increase in height and number and may protrude into the follicular lumen 
with an accompanying decrease in colloid and an increase in vascularity 
(Larsen and Ingbar 1992a).
Multinodular goitre is long standing and results from repeated cycles of 
hyperplasia and involution leading to formation of nodules of involuted 
tissue surrounded by more hyperplastic tissue. A goitre progresses from 
being diffuse and symmetrical to a multinodular goitre characterised by
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structural and functional heterogeneity with areas of functional autonomy 
(De Smet 1960).
1.4.6.3 Functional Characteristics of Simple Goitre
The increase in cell number (Wollman and Breitman 1970) is not 
exclusively due to the multiplication of epithelial cells but is also caused 
by the proliferation of capillaiy endothelia and other non-epithelial cells 
(Wollman et al. 1978, Wollman 1980, Denef et al. 1981).
In the normal human thyroid there is a highly significant correlation 
between the number of cells and the thyroglobulin content, (the mean 
thyroglobulin content is 4 %), but this relationship is lost in simple goitre 
(Rentsch et al. 1982). There is often also evidence of poor iodination, 
(Ermans 1969, Rapoport et al. 1972, Studer et al. 1974). Variability of 
structure and function among the follicles of goitrous glands leads to 
huge regional interfollicular heterogeneity (Studer et al. 1978, Milloni 
and Studer 1980) with bizarre variation in iodine turnover among single 
adjacent follicles (Studer and Ramelli 1982). Homogeneity can also be 
demonstrated (Miller et al. 1967, Miller and Block 1970). Another 
feature is variability of growth, where in one region replication may be 
rapid producing many daughter follicles and within close proximity, 
follicles may grow extremely large and become distended by excessive 
accumulation of colloid (Studer and Ramelli 1982).
The normal thyroid gland has a predictable response to TSH i.e. all
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follicles function in a similar way, they contain identically iodinated 
thyroglobulin, there is enhancement of iodide transport, thyroglobulin 
endocytosis and neosynthesis, cell replication and other follicular 
fimctions are all orchestrated in a co-ordinated manner (Tong 1974). In 
nodular goitres this is not the case and it is possible to find cold follicles, 
which no longer participate in iodine turnover, hot follicles with 
excessive iodine turnover and other follicles with assorted degrees of 
iodine turnover (Miller et al. 1967, Miller and Block 1970, Miller 1978). 
Hot follicles are thought to either start out normal and later become 
hyperactive or are hyperactive from the beginning and remain so for their 
lifetime. The same theory applies to cold follicles but they are 
characteristically inactive. It has been suggested, as a result of 
experiments on ageing mice, that normal follicles become cold by losing 
their ability to organify iodine, (Studer et al. 1978 and 1980).
1.4.6.4 Structural Characteristics
Long standing simple goitres often become nodular (Studer and Gebel 
1986, Studer 1986, Smeds et al. 1987).
This may occur in two ways:-
a) The abundance of interstitial tissue makes the smooth expansion of 
replicating follicles impossible and the goitre caimot become 
diffuse. Nearby strands of coimective tissue provide the material for 
encapsulating the goitre tissue giving it a nodule like appearance 
and peculiarities of blood supply do not permit the survival of
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follicular epithelia.
b) Where uniform follicles multiply rapidly any new follicles with a 
higher intrinsic growth rate expand at the expense of slower 
growing cells, the surrounding tissue becomes compressed, the 
follicles collapse and atrophy, the stroma survives and forms a 
capsule around the expanding cluster of follicles.
There are two types of nodules (Studer and Ramelli 1982).
i) The first is architecturally uniform, is clearly distinguishable firom 
non-nodular tissue and delineated fi'om surrounding follicles. 
Follicles are of identical structure and equal fimction and are 
considered to be true clonal adenomas or benign tumours of 
oligoclonal origin. These are by far the exception. True adenomas 
are the result of a single homogeneous family of cells in a mother 
follicle replicating at a fast rate (Failkow 1974).
ii) The large majority of nodules consists of follicles which are 
fimctionally and morphologically identical to those of non-nodular 
tissue without the homogeneity of the true adenoma. These are the 
result of the neogeneration of many daughter follicles by many 
different mother follicles.
In reality it is impossible to draw a clear line between thyroid adenomas
and heterogeneous nodules (Taylor 1980).
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1.5 Treatment of NTG
1.5.1 Thyroid Hormone
The use of thyroid extract in the treatment of myxoedema was first 
described by Murray in 1891. Once the initial enthusiasm had dwindled, 
it rapidly fell into disrepute and was not revived until almost 60 years 
later by Greer and Astwood in 1953. The logic in using T4 for the 
treatment of NTG was to suppress TSH with a resulting decline in 
thyroid growth and function (Greer and Astwood 1953).
In TSH suppression the action of T4 is independent of the origin of the 
goitre and it is important that the dose given should be sufficient to 
produce a maximal state of thyroid inactivity. Where positive results 
have been obtained it has been suggested that this method of treatment 
may be due to an immunostimulatory effect of T3 and T4. In a series of 
experiments a significant increase was seen in blastogénie response of 
various lymphoid tissues to plant mitogens following T4 and T3 
administration. This was not true however, in the case of spleen cells 
where the response was depressed. Restoration of blastogénie response 
of the lymphocytes of thyroidectomised rats following T3 therapy was 
also demonstrated (Chateijee and Chandel 1983).
In the past, studies to evaluate the efficacy of T4 in decreasing goitre size 
have been hindered by not always being randomised nor group 
controlled. There has been poor assessment of thyroid size, no tissue 
diagnosis, relatively insensitive methods for assaying serum TSH levels
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and the inclusion of patients with autoimmune goitres, which usually do 
reduce in size when T4 is given (Hedgedus et al. 1991). Occasionally 
nodules which were due to thyroid cancer were included, these may also 
be TSH dependant (Hill et al. 1976).
Recently, in an attempt to re-evaluate T4 therapy, whilst eliminating the 
aforementioned deficiencies, it was found on average that T4 had no 
significant effect on the size of solitary thyroid nodules. While there 
were a few patients where nodule size did decrease, this effect was also 
observed in the untreated group (Reverter et al. 1991). These findings 
oppose an earlier study by Morita et al. (1989), but are in agreement with 
a response to treatment in almost 60 % of patients and a mean decrease in 
thyroid volume of 25 %, in a study by Berghout et al. (1990).
Thyroxine administration for diffuse NTG is useful in the prevention of 
nodules. Radioiodine uptake should be < 0.5 %. Suppressive thyroid 
ther^y is unlikely to cause hyperthyroidism but caution must be 
exercised as there may be autonomous nodules, especially in the elderly 
(Edmonds 1992). On performing a TRH test a normal or near normal 
response would indicate that there is some suppression still in reserve and 
therapy may go ahead. treatment eradicates autonomous foci and can 
forestall future thyrotoxicosis (Larsen and Ingbar 1992c).
Several studies, have failed to find any effect of post-thyroidectomy 
treatment with T4 on recurrence of sporadic goitre and indicate that 
prophylactic use of T4 is unjustified (Geersden and Frolund 1984, 
Hegedus et al. 1987, Berghout et al. 1989). There is also a risk of 
osteoporosis after prolonged suppressive therapy with thyroid hormones
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(Ross et al. 1987, Paul et al. 1988, Wartofsky 1991).
1.5.2 "'iodine
Ablation of the thyroid gland with " 'l  in the treatment of NTG has been 
used to a lesser extent. Two large German studies have shown decreases 
in two thirds of their group however goitre size in both were clinically 
assessed (Keiderling et al. 1964, Klein et al. 1989). In some recent 
smaller studies decreases in thyroid volume ranged from 40 - 59 % 
(Hegedus et al. 1988, Nygaard et al. 1993, Wesche et al. 1995). There 
are some disadvantages to this treatment ie., substemal goitres sometimes 
swell causing intra-tracheal compression (Becker and Hurley 1971, 
Lorentzen and Blichert-Tofr 1983). Patients can also have a thyroiditis 
type reaction:- tenderness, fever, hypersedimentation, and 
hyperthyroidism caused by the release of thyroid hormones after the 
radiation induced destruction of follicular cells, this presents in 3 % of 
patients (Nygaard et al. 1993). Also hyperthyroidism which developed 3 
months post treatment with has been documented in 3 % of patients 
(Nygaard et al. 1993). There is likewise a small risk of hypothyroidism 
and also of cancer (Shore et al. 1985, Williams 1991, Cooper 1998). The 
risk of cancer appears to be dose related (Hall et al. 1992). In a large 
study Holm et al. (1988) evaluated 35,000 patients and was unable to 
demonstrate an increased frequency in any type of cancer. In rats it has 
been shown that *^ *I is a dose dependent carcinogen (Williams 1991).
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1.5.3 Surgery
Surgical intervention is rapid and effective in goitre removal but within 
10 years there is recurrence in around 10 - 20 % (Geersden and Hee 
1982b, Geersden and Frolund 1984, Berghout et al. 1989, Hegedus et al.
1991). Complications to surgery are seen in 7 - 10 % of cases (Lorentzen 
and Blichert-Tofl 1983, Jensen et al. 1986, Reeve et al. 1987, Agerbaek 
et al. 1988, Pilegaard and Hessov 1988). There is also increased 
frequency of complications seen with increasing goitre size (Agerbaek et 
al. 1988). The tendency to hypothyroidism after surgery varies from 0 - 
70 % (Lorentzen and Blichert-Toft 1983, Jensen et al. 1986) also there 
are anaesthetic complications to be considered and the risk of 
hypoparathyroidism.
1.6 Aims of this Study
There were several aims to this study:-
1. To look for the presence of thyroid growth immunoglobulins in the 
serum of a group of patients with non-toxic goitre and compare this to 
a normal control group and a disease control group.
2. To compare the three following in vitro methods of measuring cell 
proliferation
a) A colourimetric method using the dye 3-(4,5- 
dimethythiazole-2-yl)-2,5-diphenytetrazolium (MTT).
31
b) The incorporation of ^ H-thymidine.
c) A commercially available kit which measures 5-bromo-2’- 
deoxyuridine (BrdU) uptake.
3. To address the following clinically relevant questions:-
i) Was there any evidence of stimulation or suppression of 
FRTL5 cells in vitro when treated with IgG from the non­
toxic goitre group, disease control patients or normal 
controls?
ii) Did treatment with thyroxine have any effect on non-toxic 
goitre size or thyroid volume?
iii) Was there a change in serum TGI levels in non-toxic goitre 
patients after thyroxine therapy?
iv) Did serum TGI levels pre-treatment have any value in 
predicting which non-toxic goitre patients would show a 
reduction in thyroid volume after thyroxine therapy?
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Chapter Two Subjects and Methods
2.1 Subjects
2.1.1 Non-Toxic Goitre Group
The population of this study group comprised of patients with NTG 27; 
female 24, male 3, prior to suppressive therapy with thyroxine, mean age,
46.6 ±13.2 years. Within this group 20 of the patients completed a 6 
month course of suppressive therapy with thyroxine, (female 18, male 2, 
mean age 48.4 ± 13.0).
The NTG group were recruited from patients attending the thyroid clinic 
at Glasgow Royal Infirmary (GRI), who presented with goitre. Their 
suitability for entering the study was based on a clinical appraisal. The 
patients in the study all had a clinical diagnosis of goitre based on 
inspection and palpation. Goitres were described as simple, small single 
nodule or multinodular. Goitre size was estimated by the clinician and 
was referred to as 1, 2, 3, 4 or 5 times normal. The volunteers recruited 
had given their consent and were all clinically and biochemically 
euthyroid. Patients had 30 mis of venous blood taken (10 mis for thyroid 
fimction tests).
Thyroid function was assessed by measurement of serum T4, using a 
Fluorescence Polarisation Immunoassay, which combines competitive 
protein binding and fluorescence polarisation. On occasions serum T3 
was measured, also by a Fluorescence Polarisation Immunoassay. TSH
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was measured by Microparticle Enzyme Immunoassay Technology. 
These three parameters for thyroid function were measured using the 
IMX system from Abbot Laboratories UK and were carried out at the 
Institute of Biochemistry GRI.
Anti-microsomal [now known as autoantibodies to thyroid peroxidase 
(TPO)] and anti-thyroglobulin antibodies were measured at the 
Department of Immunopathology, Western Infirmary Glasgow, using kits 
from Wellcome Laboratories. The remainder of blood, taken at this first 
visit, was stored as serum at -20°C for later estimation of thyroid growth 
immunoglobulins. Cytological examination of a fine needle aspirate 
from the thyroid gland was carried out only on those nodules where 
malignancy was suspected. Arrangements for a pre-treatment ultrasound 
scan and a review appointment at three months were made.
A suppressive dose of sodium thyroxine is in the order of 0.15 - 0.2 
mg/day which corresponds to its endogenous 24 hour production (Nilsson 
et al. 1977). The goitre group were prescribed sodium thyroxine for 6 
months, 0.1 mgs/day for one month which was increased to 0.2 mgs/day 
for the remaining 5 months. Side effects from T4 can include the 
following:- cardiac arrhythmia’s, angina, tachycardia, muscle cramps, 
headache, restlessness, excitability, flushing, sweating, diarrhoea and 
excessive weight loss.
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2.1.2 Disease Control Group
2.1.2 (a) Multiple Sclerosis
Patients with multiple sclerosis (MS) 10; (female 9, male 1, mean age,
39.7 ± 8.4 years). These subjects attended the neurology out patient 
clinic at the Southern General Hospital, Glasgow. Patients were selected 
according to a clinical diagnosis of probable multiple sclerosis, which 
was supported by a positive oligoclonal pattern in the cerebrospinal fluid 
(CSF).
Multiple sclerosis is a demyelinating disease of the central nervous 
system. Its cause and pathogenesis are unknown but it is well linked with 
environmental and genetic factors. It affects approximately 1 in 700 
people in the United Kingdom, age range at onset is from 10-59  years 
and mean age at onset approximately 29 - 33 years (Acheson 1985). In 
general early onset MS is accompanied by the most severe symptoms. 
There is general agreement that it is more common and that age of onset 
is slightly earlier in females than in males. A female to male ratio of 1.4 : 
1 was found by (Acheson 1985), although one of the larger and more 
reliable American studies quotes 1.8 : 1 (Kurtze 1979). The higher 
incidence in females is thought to reflect a hormonal factor affecting 
susceptibility. The rise and fall of the incidence of MS corresponds 
closely with puberty and with the menopause (Fischman 1982). Other 
autoimmune diseases such as Hashimoto’s thyroiditis and systemic lupus 
erythematosus (SLE) are also more common in females than males.
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Multiple sclerosis shows an organ specific immune response directed 
against a target antigen within and restricted to the myelin sheath. The 
pathological lesion is a plaque which is an area of white matter in which 
myelin and oligodendrocytes are absent. Axons denuded of their myelin 
sheath are poor conductors of nerve impulses, giving rise to a 
neurological deficit.
2.1.2 (b) Environmental Factors
It is common in temperate climates, with a well recognised North/South 
gradient in the USA and Europe (Limburg 1950). Studies on migrants 
have shown that they assume the local risk of contracting MS if they 
migrate before the age of 15, but if they go later they retain the risk 
associated with their country of origin (Kurtze 1970). On occasion there 
have been epidemics, which have been accompanied by the proposal of a 
viral infective agent.
2.1.2 (c) Genetic Factors
Genetic factors are important as can be seen fi"om the occurrence of MS 
in Caucasians. Its association with HLA-DRW2 antigens in both 
Northern Europeans and Americans is well documented (Jersild et al.
1972). Where MS is diagnosed in a family it is not unusual to find it in 
other siblings. There is also familial aggregation, indicating that it may 
be in part due to exposure to a common environmental influence, with
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relatives being prone to other organ specific diseases (Bobowick et al. 
1978).
2.1.2 (d) Diagnostic Criteria (McAlpine 1972)
Clinically definite multiple sclerosis is demonstrated by a history of acute 
retrobulbar neuritis or an episode of paraesthesiae, motor weakness, 
double vision, unsteadiness in walking and other signs of multiple lesions 
in the central nervous system. These may be minimal for many years, 
symptoms may improve or clear up and may be followed by re lises 
during the course of years. Later there is gradual onset of paraplegia 
followed by relapses and signs indicative of disease in the brain stem, 
cerebrum and optic nerve.
Probable multiple sclerosis; during the original attack, there is evidence 
of multiple lesions, this can be followed by a good recovery. There may 
be complete absence of fi*esh symptoms for a year with the return of 
original symptoms and the ^pearance of an extensor plantar response, 
nystagmus, tremor or temporal pallor of an optic disc and a history of one 
or more attacks of retrobulbar neuritis.
Possible multiple sclerosis has a similar history to that described in 
probable MS but with unusual features, or insufficient follow-up 
information. A patient may have a history of progressive paraplegia 
usually in early middle age with no evidence of relapse or remission, or 
of a lesion outside the spinal cord. When doubt exists attention is paid to
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the age of the patient, a positive family history and laboratory findings in 
the cerebrospinal fluid (CSF). Diagnosis is assisted by expert 
neurological assessment, imaging (especially magnetic resonance 
imaging) and evoked potentials, such as visual evoked potentials.
Laboratory support is confined to the presence of one or more specific 
IgG bands, in the gamma globulin region when concentrated CSF is 
applied to agar gel electrophoresis (Lowenthal 1964). The more recent 
introduction of polyacrylamide gel electrophoresis has improved this 
diagnostic aid along with the refinement of calculating the CSF- 
IgG/albumin ratio in relation to the simultaneous serum levels (normal 
range 4 - 2 2  %). This expression in relation to another protein i.e. 
albumin which is not synthesised in the brain indicates the integrity of the 
blood brain barrier thereby eliminating other neurological diseases 
(Waigt 1980). There is some evidence that breach of the blood brain 
barrier may be a temporary phenomenon. This was shown in 
experiments in which isotope was administered and the brain scanned, 
the presence of isotope in the brain parenchyma indicated escape through 
the barrier. After 4 weeks, on repetition of the experiment, no 
abnormality was found (Gize and Mishkin 1970, Cohan and Fermalich 
1975). Approximately 94 % of MS patients have a positive oligoclonal 
pattern, or increased production of IgG in the CSF (Thomson et al. 1979). 
The presence of this oligoclonal IgG appears to be independent of the 
clinical activity or type of the disease and is not abolished by 
immunosupression. In multiple sclerosis the total protein concentration
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in the CSF is usually normal or only slightly elevated (normal range 0 -
0.4.g/1). This test is not entirely specific for MS as it is also positive in 
neurosyphilis, subacute sclerosing panencephalitis (SSPE) and Guillain- 
Barre syndrome (Waigt and Zgorzalewicz 1982). The presence of red 
blood cells in the CSF invalidates the test.
2.1.2 (e) Autoimmune Associations
Multiple sclerosis is not universally accepted as an autoimmune disease, 
however evidence of the autoimmune nature of MS is supported by the 
following abnormal immunological findings:-
1. Abnormal immunoglobulins can be found in the CSF protein, within 
the central nervous system (CNS) compartment.
2. It is common to find high titres of viral antibodies, especially measles 
(Adams and Imagawa 1962, Norrby 1978).
3. There are T cell subset abnormalities especially in relapses of the 
condition.
Like non-toxic goitre, MS is influenced by genetic and environmental 
factors, environmental probably being the most important. In 
autoimmune disease the state of self tolerance is lost, i.e. the body’s own 
‘self cells and molecules stimulate an immune response whereby the 
body’s own structures are attacked. Whilst both MS and NTG are 
thought to be autoimmune in nature they are both disorders of non­
specific immunity and although there are aetiological similarities between
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both diseases, the clinical manifestation of one is remote from that of the 
other. It was for these reasons MS was chosen as a suitable disease 
control group, besides providing readily available samples of the required 
age and sex. The MS samples for this study were provided by Dr Hugh 
Willison at the Institute of Neurological Sciences Southern General 
Hospital Glasgow. These were received as serum samples and were 
frozen on receipt.
2.1.3 Normal Control Group
The normal control group (NC) numbered 27; (female 24, male 3, mean 
age, 46.6 ± 12.4years).
These were a group of normal individuals recruited mainly from 
laboratory staff at the Department of Medicine GRI. They were not 
known to have any current or past history of thyroid disease, nor any 
autoimmune disease. The normal control group included 24 females, of 
these 12.5 % were taking the oral contraceptive pill, 12.5 % were 
receiving hormone replacement therapy and the remaining 75 % were 
hormone free. They were also comparable for age and sex with the NTG 
and MS groups. Fifty per cent of the normal control group, were 
laboratory staff, while the remainder were students associated with the 
department and clerical staff. This group had 20 mis of venous blood 
taken.
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2.2 Thyroid Imaging (McDougall 1992)
Thyroid ultrasound scans were performed at the X-ray department GRI, 
using an ALT Ultramark 9 scanner, confirming the diagnosis of goitre 
and providing thyroid volumes and dimensions.
Ultrasonography is a non-invasive, rapid, simple and relatively 
inexpensive method for studying the thyroid gland. The patient lies 
recumbent with neck extended. A sound wave of very high frequency (5 
- 10 MHz) is pulsed into the area of interest, the echoes are detected by 
the receiver and reproduced as an image. Solid tissue produces many 
echoes at tissue interfaces and gives excellent resolution, theoretically 
<1 .0  mm in the axial direction and 1 .0 - 2  mm in the transverse direction 
(Scheible et al. 1979).
This method has an error of ^proximately ± 16 % for nodules with a 
volume of between 8  and 70 mis (Nygaard et al. 1996), this can be 
improved to ~ ± 10 % if cross sections are scanned at 0.5 cm intervals 
and the results computer calculated (Rasmussen and Hjorth 1974), even 
with this error it is still more accurate and reproducible than palpation 
(Ashcraft and Van Herle 1981a, Brunn et al. 1981, Gutekunst et al. 1986, 
Hay et al. 1986). In a study of clinically assessed goitre size, inter and 
intra-observer variation ranged from 0 - 170 % with an average error of 
39 % when compared to those ultrasonically determined, giving poor 
correlation (Jarlov et al. 1991).
The sound beam is a major limitation in ultrasonography as it will only 
penetrate tissue a distance of 4 cm at 10 MHz. Fortunately in most
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patients the thyroid gland lies within 4 cm of the skin surface enabling it 
to be imaged completely. Other inaccuracies of this method are chiefly in 
underestimating the volume of large multinodular goitres, where the 
shape may not be ellipsoidal and coupling the transducer to the neck 
surface may not be possible. Unfortunately it does not show differences 
in tissue characteristics and patients with intrathoracic thyroid tissue can 
prove problematic. Advantages include safety for patients as no ionising 
radiation is used, there is no patient preparation required and finally 
patients are not required to stop any medication before being scanned. 
Ultrasound is also helpful in obtaining accurate measurement of the size 
of a nodule, if suppressive ther^y is being used. Measurements taken 
regularly can show whether or not a nodule is growing and allows 
accurate calculation of thyroid gland volume. Thickness, width and 
length of both lobes are measured and thyroid volume calculated using 
the formula for a spherical ellipsoid.
Total thyroid volume = AP (cm) x width (cm) x length (cm), where AP is 
the anteroposterior diameter (Brunn et al. 1981).
In this study, a response to treatment was defined as a decrease in thyroid 
size of 2 0  % or more at the end of the follow-up as this degree of change 
is outwith the range of error of the method.
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2.3 Sample Preparation
Serum was obtained by centrifugation of clotted blood at 2500 g for 10 
minutes. This was stored at -20°C until required.
2.4 Gamma Globulin Separation
2.4.1 Separation of 7S Gamma Globulin
Gamma Globulin was separated from undialysed human serum using a
two-stage batch procedure employing high resolution Sephacryl S-200 
(Baumstark et al. 1964). In the procedure of gel filtration molecules are 
separated according to differences in their sizes. This method was 
chosen for its low cost, speed and ease of use. It does however produce a 
crude preparation of IgG. As the DEAE sephadex used in the Baumstark 
method is now obsolete, Pharmacia recommended replacing it with 
Sephacryl S-200.
Immuno-electrophoresis was carried out (figure 2.1), at the Institute of 
Biochemistry GRI, on the IgG sample prepared from the serum obtained 
from the Blood Transfusion Service (BTS) (section 2.4.4). This 
demonstrates that the sample is concentrated IgG, with a degree of 
contamination by other serum proteins.
Immuno-electrophoresis is a powerful analytical technique with great 
resolving power, as it combines prior separation of antigens by
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electrophoresis with immuno-diffiision against antiserum. The antigen 
diffuses from a point source after the initial electrophoresis and interacts 
with the antiserum advancing on a plane front producing clearly defined 
arcs of precipitation at equivalence.
Figure 2.1 Immuno-electrophoresis of Normal IgG
I
A««f« -
Immuno-electrophoresis was carried out on the IgG prepared from the 
normal serum sample obtained from the BTS. This shows concentrated 
IgG, although there are other serum proteins also present.
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2.4.2 Materials and Equipment
Sephacryl S-200 (Pharmacia)
Phosphate Buffer 0.01 M (pH 6.5); KH2PO4/K2 HPO4 molar ratio 2.45 
(BDH)
HCL 0.5 N (BDH)
NaOH 1.0 N (BDH)
K2HPO4 I.OM 
pH meter (BDH)
Minisart filters 0.2 microns (Sartorius)
Watman number 1 filter papers (BDH)
Scintered glass funnel (BDH)
Conical side armed filter flask (BDH)
2.4.3 Gel Preparation
The Sephacryl gel, which comes pre-swollen and with fines removed, 
was washed with 1 litre of 0.5 N NaOH followed by distilled water until 
the effluent was free of alkali. The gel was then washed with 1 litre of 
0.5 N HCL followed by distilled water until the effluent was free of acid. 
The preparation was suspended in 800 ml of distilled water and the pH 
adjusted to 6.5 with 1 N NaOH. The slurry was allowed to settle for 5 
minutes, the supernatant liquid decanted and resuspended in 0.01 M 
phosphate buffer pH 6.5. The gel was allowed to stand with occasional
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stirring for 15 minutes. It was then filtered and washed slowly on a 
Buchner funnel with IL of cold 0.01 M phosphate buffer pH 6.5. This 
was stored at 4°C in 0.01 M phosphate buffer pH 6.5 to which some 
absolute alcohol had been added as preservative.
2.4.4 Method for 7S Gamma Globulin Separation
1.5 mis of serum was added to 3.0 grams of Sephacryl S-200. This was 
kept at 4°C with occasional stirring. After 1 hour the slurry was filtered 
using a scintered glass fimnel and a double layer of Watman No 1 filter 
papers, then washed with 4 x 2.5 ml volumes of 0.01 M phosphate buffer, 
taking the sephacryl to dryness. A further 5 mis of 0.01 M phosphate 
buffer was added to the filtrate and mixed for 60 minutes at 4°C, after 
which the resin was again washed with 10 x 2.0 ml volumes of 0.01 M 
phosphate buffer and taken to dryness as before. The filtrate pH was 
immediately adjusted to 7.5 with 1.0 M K2HPO4 and filter sterilised 
using a 0.2 p Minisart filter. These IgG samples were then aliquoted and 
stored fi-ozen at -20°C for further use.
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2.5 Protein Content of IgG Samples
At the outset it was decided to estimate the protein content based on its 
absorption of UV light at 280 nm, which it does in a concentration 
dependent manner (Hudson and Hay 1989a).
Total protein concentration (mg/ml) = 1.55 x A280 - 0.77 x A260 
Although this is a simple and direct means of estimating the total protein 
content of a solution it is faulted by the fact that many detergents and 
some buffers absorb strongly at this wavelength. The bovine serum 
albumin (BSA) quality control (section 2.5.2) which had been diluted in 
order to give a final protein concentration of 600 pg/ml when measured, 
did not give this value. The method was repeated many times without 
success. The only explanation was perhaps that samples and the QC 
material were diluted in phosphate buffer and not the recommended 0 .2  
M NaCL. This method for estimating total protein was not pursued 
further and that of Lowry used in its place (section 2.5.3).
2.5.1 Estimation of Total Protein (Hudson and Hay 1989b)
The Lowry method is essentially a biuret reaction which uses Folin- 
Ciocalteau reagent to enhance colour development. It is used 
preferentially as it is 1 0  times more sensitive than the biuret reaction 
(Lowry et al. 1951).
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Different concentrations of a known protein are treated with alkaline 
copper sulphate in the presence of tartrate. Following incubation, the 
Folin phosphotungstomolybdic acid reagent is added. This is reduced to 
a blue colour and is read at 650 nm. The unknown protein solutions are 
converted into concentration units by reference to the standard curve. 
Shortcomings of the method are that (i) the alkaline copper reagent is 
unstable and requires fresh preparation for each assay (ii) the assay is 
photosensitive and care should be taken to ensure that samples are 
subjected to the same amount of light (iii) interference is common from 
substances such as detergents, carbohydrates, glycerol, disulphide 
containing compounds, magnesium and calcium. In other ways the assay 
is rapid, technically simple and reliable.
This adaptation (Hudson and Hay 1989b) of the Lowry method differs 
from the original in that absorbances are read at 650 nm and not 750 nm. 
To demonstrate that this made no difference to the results 26 samples of 
BSA (600 pg/ml) were analysed and read at both wavelengths. Statistical 
comparison was carried out using a Mann Whitney U Test. Both sets of 
results are shown in table 2.1. No significant statistical difference could 
be demonstrated between the results at these two different wavelengths, p 
= 0.41 enabling either wavelength to be used, but because the method of 
Hudson and Hay stated 650 nm that was the wavelength used. At 650 nm 
mean = 667.2 ± 42.9 (ISD.), cv = 6.5 % and at 750 nm mean = 672 ± 
37.9 (lSD.),cv = 5.6%.
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Table 2.1 Total Protein QC measured at 2 wavelengths
Total protein conc. 
650 nm
(pg/ml)
750 nm
665 670
685 700
685 690
670 700
770 765
580 600
615 630
685 700
620 630
630 650
630 650
645 655
700 705
675 680
705 700
680 690
660 665
615 630
650 640
640 660
650 650
760 750
640 650
700 710
645 660
630 645
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2.5.2 Materials and Equipment
Stock protein standard; human serum albumin (HSA); 1 mg/ml in 0.01 M 
PB (Sigma)
Unknown protein solutions
Sodium carbonate; 2 % w/v in 0.1 M NaOH.
Cupric sulphate; 1 % w/v in distilled water.
Folin and Ciocalteu’s reagent (BDH)
Spectrophotometer 
Phosphate buffer 0.01 M (PB)
BSA; 600 pg/ml in 0.01 M PB (Sigma)
Bovine serum albumin prepared at the above concentration was used as a 
quality control check in the protein method. It was aliquoted, stored 
frozen at -20°C and analysed with each protein assay.
2.5.3 Total Protein Method (Hudson and Hay 1989b)
A standard curve as detailed in table 2.2 was prepared and dilutions of 
the unknown protein solutions, usually 1/8 or 1/10, were made in PB. 
The total protein was measured as follows; equal volumes of copper 
sulphate and sodium potassium tartrate solutions were combined. One 
ml of this mixture was removed and mixed with 50 ml of sodium 
carbonate solution. One ml of this final mixture was added to 100 pi of 
each of the standards and unknown protein solutions to be determined.
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Finally 100 pi of Folin Ciocalteu’s reagent was added to each tube, 
mixed vigorously and incubated at room temperature for 15 minutes. 
Absorbances were read at 650 nm and by plotting values against 
concentrations of the standard solutions, the protein concentrations of the 
unknown solutions were determined.
2.5.4 Total Protein Standard Curve Construction
Stock HSA (1 mg/ml) was diluted in 0.01 M PB. to produce 
concentrations ranging from 1 0 0  - 1 0 0 0  pg/ml.
Table 2.2 Standard Curve Construction
HSA conc. pg/ml Volume (pi) of HSA Volume (pi) of 0.01 
M(PB)
0 0 1 0 0
1 0 0 1 0 90
2 0 0 2 0 80
300 30 70
400 40 60
500 50 50
750 75 25
1 0 0 0 1 0 0 0
A typical standard curve is shown in figure 2.2 when the concentrations 
above are plotted versus absorbance. A new standard curve was 
constructed for each batch of proteins assayed.
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Figure 2.2 Total Protein Standard Curve
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Total protein standard curve, showing concentrations of HSA from 100 
1000 pg/ml plotted vs absorbance of light at 650 nm.
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In the preceding methods the gamma globulin prepared from each of the 
samples in each of the groups was analysed for protein content using the 
method of Lowry (1951) adapted by Hudson and Hay (1989b) (section 
2.5.3). These IgG rich preparations from the NTG patients, disease 
control group and normal controls were then diluted in ’O’H + 0.1 % 
BSA media to give a protein concentration of 100 pg/ml (once the 
optimum IgG concentration had been established section 2.8.8) and 
stored at -20°C for use in each of the proliferation assays.
2.6 FRTL5 Cell Line
The FRTL5 cell line, is a non-transformed, differentiated strain of thyroid 
follicular cells derived from adult Fischer rats. They express important 
aspects of thyroid differentiation, i.e. the synthesis and secretion of 
thyroglobulin, trapping and concentrating iodide but do not organify it 
and as a consequence produce no thyroid hormones. This cloned cell line 
is totally dependent on TSH at physiological concentrations for cyclic 
AMP stimulation and growth and can be maintained in culture 
indefinitely, providing large quantities of a homogeneous functional 
thyroid cell population for study (Ambesi-Impiombato et al. 1980).
53
2.6.1 Problems Encountered with the FRTL5 Cell Line
2.6.1 (a) Contamination
On occasion cultures were contaminated with yeast but more frequently 
with fungus (mould). Contamination was not observed when cells were 
grown in flasks passaged weekly. However, assays carried out in micro- 
titre plates are more open and therefore more susceptible to airborne 
infection and maintaining them for 14 days with no contamination 
became increasingly difficult. The precaution of filter sterilising media 
which already contained antibiotics, penicillin/streptomycin (P/S), 
gentamycin and fungizone before use did not resolve the problem. As the 
amount of fungizone used was relatively small (0.25 pg/ml) it was 
decided to increase this 5 fold to 1.25 pg/ml. This had the desired effect 
with no ^parent toxic effect to the cells. Fungizone can be used safely 
up to a concentration of 10 pg/ml (Hudson and Hay 1989c).
2.6.1 (b) Cell Passage
Collagenase and trypsin in chicken serum (CTC) was used to remove the 
adherent FRLT5 cells (section 2.6.2). This worked well but when it came 
to counting it was evident that the cells were in clumps and not single cell 
suspensions as expected. The clumping could not be tolerated if accurate 
cell counting and plating out at specific concentrations was to be 
achieved. Vigorous mixing with a pastette was not effective enough. A
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cytospin was used in an attempt to evenly distribute the cells onto slides, 
this also was ineffective and only after checking the original paper of 
Ambesi-Impiombato et al. (1980), it was discovered that in transcribing 
the method the ethylenediaminetetraacetic acid (EOTA) had been omitted 
from the CTC solution.
2.6.2 Method of Cell Passage
Once the cells have grown to confluence, they are passaged weekly. This 
is done with a split ratio of 1/10, using a 5 ml mixture of CTC, containing 
collagenase, 20 units per ml, trypsin, 0.75 mgs/ml and 2 % heat 
inactivated chicken serum, all in calcium and magnesium free Hanks 
Balanced Salt Solution (HESS). EDTA is added as a 0.2 M solution in 
1.0 M NaOH/HBSS, 1:1.  Cells were removed by the addition of one 5 
ml aliquot of CTC to a 75 cm  ^flask containing the adherent FRTL5 cells 
and incubated at 37°C for 20 minutes. Cells were washed with 6 H 
medium to remove the CTC and resuspended in 1 ml of 6 H, in 
preparation for counting.
After passage the FRTL5 cell concentration was calculated as follows.
A 16 dilution of cells in Trypan Blue dye was counted in a 
haemocytometer (Weber Scientific Ltd, Middlesex England), the 
exclusion of the Trypan Blue indicating live cells. Cells should be at 
least 80 % viable.
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4
Cell concentration /ml = number of cells counted x dilution factor x 10
4
(10 represents the area of the 4 x 4 matrix of the haemocytometer).
2.7 MTT Proliferation Assay (Mosmann 1983)
This cell proliferation method is used routinely in our department and 
was to prove useful in providing a convenient starting point from which 
to develop the MTT assay. In section 2.7.3.1 - 2.7.3.3 the method is 
optimised, (the results obtained influenced the decision to switch to that 
used by Claffey et al. 1993).
FRTL5 cells were cultured according to Ambesi-Impiombato et al. 
(1982). A colourimetric assay using 3-[4,5-Dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide (MTT) was used to quantify cell 
proliferation (Mosmann 1983).
2.7.1 Materials and Equipment
6 H media (section 2.8.2)
5H media (6 H without bovine TSH)
Acidified Triton X (10 % Triton X in 0.04 N HCL)
MTT 5 mgs/ml in PBS (Sigma)
Equipment see section 2.8.2
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2.7.2 Method
A single cell suspension of FRTL5 cells at a concentration of 1 x 10^/ml 
in 6 H media was plated out into 96 well flat bottomed plates, 100 pi / 
well.
After a growing period of 4 days, the cells were washed with 1 x HBSS 
and the media replaced with 100 pi of thyrotrophin free media (5H). The 
cultures were thus maintained, feeding every 72 hours.
After 7 days and in triplicate, 100 pi of the IgG samples were added and 
incubated for 72 hours at 37°C in a humidified atmosphere of 5 % CO2. 
MTT, 10 pi per 100 pi medium was added to all wells and plates 
incubated at 37°C for 4 hours. The plates were inverted and drained onto 
absorbent paper, this was followed by the addition of 1 0 0  pi of acidified 
Triton X to each well. The plates were then mixed for 20 minutes to 
dissolve the dark blue crystals and absorbances read within 1 hour, at test 
wavelength 570 nm, reference wavelength 630 nm and calibration setting 
1.99 (Mosmann 1983).
Caution must be exercised when handling MTT as it may cause heritable 
genetic damage.
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2.7.3 Method Development
2.7.3.1 Establishing Optimum FRTL5 Cell Concentration
To establish the optimum FRTL5 cell concentration 3 different 
concentrations of FRTL5 cells were used, ranging from 0.25 to 1.0 x 
lOVml. These were used in conjunction with the “low QC” material 
(section 3.1.2), which had been diluted to give an IgG concentration of 
100 pg/ml. Results are shown in figure 2.3. As a result of this a cell 
concentration of 0.5 x 10^/ml was chosen for further experiments, as at 
this concentration the graph shows that there was still potential growth.
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Figure 2.3 Optimum FRTL5 Cell Concentration
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To define optimum FRTL5 cell concentration the low QC material, IgG 
concentration of 100 pg/ml, was analysed in conjunction with FRTL5 
cells at 3 different cell concentrations; 0.25, 0.5 and 1.0 x 10 /^ml (n = 3). 
0.5 X 10^/ml was chosen as the optimum cell concentration.
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2.T.3.2 Optimum IgG Concentration
In order to establish the optimum IgG concentration four concentrations 
of, again, the low QC material were analysed ranging from 50 - 200 
pg/ml and using an FRTL5 cell concentration 0.5 x 10 /^ml. Results of 
this can be seen in figure 2.4. Results indicated that 100 pg/ml would be 
the best IgG concentration to use. On reflection it would have been more 
advantageous to combine the optimum FRTL5 cell concentration with 
optimum IgG concentration in one assay, but apart from this the main 
concern was that absorbances were very low.
2.7.33 Dose Response to TSH
Bovine TSH (10 lU/ml) was diluted to a concentration of 100 mU/ml and
a range of concentrations from 0.1 - 50 mU/ml made from this, table 2.3.
Figure 2.5 shows the proliferative response of FRTL5 cells at 0.5 x 
lOVml to concentrations of bovine TSH which ranged from 0.1 - 50 
mU/ml.
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Table 2.3 TSH Concentrations used to Demonstrate Dose 
Response
TSH conc. mU/ml Volume (pl) of TSH 
(100 mU/ml)
Volume (pl) of 5H 
media
0 .1 1 0 9990
1 .0 1 0 990
2 .0 2 0 980
1 0 .0 1 0 0 900
2 0 .0 1 0 0 400
30.0 150 350
40.0 2 0 0 300
50.0 250 250
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Figure 2.4 Optimum IgG Concentration
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Four different IgG concentrations of the low QC were analysed using an 
FRTL5 cell concentration of 0.5 x 10 /^ml (n = 3). From the results 
obtained 100 pg/ml was chosen as the optimum IgG concentration.
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Figure 2.5 Dose Response to Bovine TSH
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Dose response to bovine TSH was assessed by using concentrations of 
bovine TSH from 0.1 - 50 mU/ml (n = 3).
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Two different samples were used to estimate the intra-assay variation; 
sample A from the goitre group, chosen at random and sample B the low 
QC. The results are shown in table 2.4. Although the sample size was 
small it was thought that this could only account in part for the poor 
cv.’s. Even after optimising for FRTL5 cell concentration and IgG 
concentration, there was no improvement in the low absorbances. It was 
decided at this stage to look for an alternative method. As previously 
mentioned this was achieved by changing to that of Claffey et al. (1993). 
Claffey uses OH + 5 % NCS and points out that by removing the 5 
hormones from the culture media the sensitivity to these 5 hormones is 
diminished and at the same time the specificity of the bioassay is 
enhanced (Claffey et al. 1993).
Table 2.4 Intra-assay Variation
Sample A Sample B
n 8 8
mean 0.047 0.031
SD 0.018 0.008
% cv 38 27
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2.8 Assessment of Cellular Growth
2.8.1 Assessment of Cellular Growth using MTT (Claffey et al.
1993)
This is a rapid, simple, colourimetric assay used for quantifying cellular 
growth and survival, showing a high degree of precision in which the 
mitochondrial enzyme succinate dehydrogenase of live cells reduces the 
yellow dye MTT to a water insoluble purple formazan product (Slater et 
al. 1963). The end product is solubilised and measured colourimetrically 
(Mosmann 1983). The amount of formazan generated is directly 
proportional to the cell number over a wide range, using a homogeneous 
cell population. The intracellular mechanism for formazan production is 
as yet unknown. One recent study has used 5-(3- 
carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl) 
tétrazolium, inner salt (MTS) a contrasting tétrazolium salt and compared 
it with MTT. The aim of this was to elucidate the electron transfer 
pathway (Goodwin et al. 1996). The main advantages of this 
colourimetric assay are the speed with which samples can be processed 
and its non-use of radioisotopes.
2.8.2 Materials and Equipment
FRTL5 cells:- a gift fi'om Dr N Marshall (University College and 
Middlesex School of Medicine London).
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Fungizone 0.5 % Amphotericin B 250 pg/ml (Gibco BRL UK)
Hanks balanced salt solution (Gibco)
Heat inactivated chicken serum (Gibco)
BSA, Collagenase, Trypsin, (all Sigma)
Triton X, 10 % in 0.1 M HCL (Hopkin & Williams UK.)
EDTA and NaOH (BDH)
Dynatech MR 700 microtitre plate reader
75 cm^ tissue culture flasks, 96 well microtitre plates (Nunc, Roskilde, 
Denmark)
Phosphate buffered saline (PBS) (Oxoid Ltd England)
Shaker (Luckham PLC UK)
37°C incubator with humidified atmosphere of 5 % COi/air 
Laminar flow cabinet 
MTT 5 mgs/ml in PBS.
Materials for 6H Media Preparation
This 6 hormone mixture plus non essential amino acids (Gibco) and 5 % 
heat inactivated new bom calf serum forms the working solution of 
FRTL5 growth medium. Its constituents are as follows
Coon’s modified Ham’s F12 medium (Life Technologies Ltd Paisley 
Scotland), supplemented with the following hormones and at the 
following final concentrations; Somatostatin 10 ng/ml (Calbiochem), 
Bovine TSH 10 mU/ml (Armour, Pharmaceuticals, Illinois, USA),
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Hydrocortisone 0.36 ng/ml, Transferrin 5 pg/ml, Glycyl-L-Hystidyl-L- 
Lysine Acetate 10 ng/ml. Insulin 10 pg/ml (Sigma). All of the 
aforementioned were stored in aliquots at -70°C. P/S, 5000 IU/ml/5000 
pg/ml (Sigma), (5 mls/500mls Coons medium), Gentamycin 40 pg/ml 
(Roussel Ltd, Dublin, Republic of Ireland) (1 ml/500 mis Coons 
medium). Glutamine 200 mM (5 mls/500 mis Coons medium).
2.8.3 Cell Proliferation Method
4
FRTL5 cells, were seeded at a density of 5 x 10 /ml in 6H medium into 
96 well flat bottomed plates (150 pl/well).
After 4 days at 37°C the 6H medium was removed and replaced with 
‘O’H medium which retained the 5 % NCS, 1 % glutamine, 1 % P/S and 
fungizone 0.5 % but lacked the hormones and supplements. The cultures 
were maintained thus in order to achieve quiescence, with media 
replacement every 72 hours.
At approximately 70 % confluence and after a period of 9 days the 
cultures were washed with ‘O’H medium supplemented with 0.1 % 
Bovine serum albumin, P/S, glutamine and fungizone as above. 
Triplicates of growth factors or test substances which had been diluted in 
‘O’H + 0.1 % BSA to give protein concentrations of 100 pg/ml were 
incubated with the cells for 48 hours at 37°C using a final volume of 100 
Ml
Prior to use the MTT was terminally filtered to sterilise it and to remove
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any insoluble residue. After the 48 hour incubation with selected 
stimulators 10 pi MTT was added per well and incubated for a further 30 
minutes at 37°C. The plates were inverted and blotted on absorbent 
paper. The formazan was then eluted from the cells by the addition of 50 
pi of acidified Triton X-100 (10 % Triton X in 0.1 M HCL). The 
microtitre plates were mixed gently for 20 minutes at room temp. 
Absorbances of the wells were read on a Dynatech plate reader, within 
one hour of stopping the reaction. The test wavelength was 595 nm, 
reference wavelength 655 nm and the calibration setting 1.99 (Mosmann 
1983).
The following amendments were made to the method during the course 
of this project.
1. The mixing period with acidified Triton X to dissolve the blue crystals 
was extended by 20 minutes to 40 as some crystals still appeared un­
dissolved.
2. It was decided not to use the outer wells of the plates, as triplicates of 
results at the edges were not good. This was most likely due to 
evaporation in the outer wells. Sterile water was used to fill these 
wells in place of samples, the only drawback being a decrease in the 
number of samples processed per plate.
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2.8.4 Optimising Conditions for MTT Cellular Growth
2.8.5 FRTL5 Growth Curve
In the log phase, cell growth is asynchronous and exponential and is the 
optimum time for cell use as the population is phenotypically at its most 
homogeneous and has its highest viability. By establishing the doubling 
time of the cells one is assured that the cells will be in the log phase 
(Hudson and Hay 1989c).
2.8.6 Growth Curve Method
1 ml of FRTL5 cells was added to each well of a 24 well plate at a cell 
concentration of 2.5 x lO' /^ml. At intervals of 24 hours 1 ml of media 
was removed from each of two wells and retained. Two hundred 
microlitres of CTC was added to each of the two wells and incubated for 
5 minutes at 37°C, then 800 pi of the retained media was added to each 
well giving a final volume of 1 ml. Cells were then diluted x 2 in trypan 
blue to assess viability and counted as in section 2.6.2. This procedure 
was carried out over a period of 12 days. Table 2.5 shows the data 
obtained and figure 2.6 the FRTL5 cell line growth curve drawn from this 
data. The doubling time of the cells was approximately 30 hours.
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Table 2.5 Growth Curve Data
Time in days Mean No of cells 
xlO^/ml
0 2.5
1 1.0
2 2.0
3 4.1
4 8.4
5 9.3
6 11.0
8 13.0
11 14.0
12 7.5
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Figure 2.6 FRTL5 Growth Curve
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FRTL5 cells were seeded at a density of 2.5 x 10 /^ml. Cells were 
removed and counted daily, the curve demonstrates the growth phases of 
the cell line n = 3.
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2.8.7 Demonstration of Quiescence
In order to demonstrate that FRTL5 cells quiesced upon removal of TSH 
from the growth media, a growth experiment as previously described in 
section 2.8.6 was carried out. On day 5 the FRTL5 cells in culture were 
divided into 2 groups, one fed with 6H media and the other with ‘O’H + 
5 % NCS media. The growth of each group was followed daily. Figure
2.7 shows that the cells which were switched to ‘O’H + 5 % NCS reached 
a plateau at day 7 and those grown in 6H at day 14, demonstrating that 
the removal of TSH from the culture media resulted in the quiescence of 
the FRTL5 cells.
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Figure 2.7 Growth Curve of FRTL5 Cells Showing Quiescence
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Growth experiment demonstrating the effect on FRTL5 cells after the 
removal of TSH fi-om the growth medium (represented by the closed 
boxes). The growth plateau is reached at day 7 whereas those in 6H 
(with TSH) do not plateau until day 14.
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2.8.8 Optimum IgG and FRTL5 Cell Concentration
Preliminary experiments were carried out in order to define optimum IgG 
concentration, optimum FRTL5 cell concentration and dose response to 
TSH. Figure 2.8 shows four FRTL5 cell concentrations ranging from 1 x 
10^  - 1 X 10^ . These were assayed in combination with 3 IgG 
concentrations made from the low QC material from 50 - 200 pg/ml. The 
concentration of IgG chosen for use was 100 pg/ml as this was halfway 
on the gr^h , thus allowing any growth or inhibitory effect to be 
observed. The FRTL5 concentration chosen was 5 x 10"^  as this appeared 
to give the maximum signal.
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Figure 2.8 Optimum FRTL5 and IgG Concentrations
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FRTL5 cell concentrations ranging from 1 x 1 - 1 x 1 0 ^  in combination 
with IgG concentrations from 50 - 200 |ig/ml were assayed 
colourimetrically using MTT (n = 3).
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2.8.9 Dose Response to Bovine TSH
As described in table 2.3 bovine TSH (10 lU/ml) was diluted to 100 
mU/ml and a range of concentrations from 0.1 - 50 mU/ml made from 
this. This dose response to TSH is shown in figure 2.9 (a). The response 
appeared to be tri-phasic, the experiment was repeated but using 
concentrations of TSH which covered a narrower range (0.025 - 10 
mu/ml). This result is shown in figure 2.9 (b).
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Figure 2.9 (a) MTT Dose Response to Bovine TSH (0.1 -50 mU/ml)
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FRTL5 cells were incubated with dilutions of bovine TSH ranging from 
0.1 - 50 mU/ml (n = 3). MTT was used to measure the effect of these 
different TSH concentrations on proliferation.
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Figure 2.9 (b)MTT Dose Response to Bovine TSH (0.025 -10 mU/ml)
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FRTL5 cells were exposed to dilutions of bovine TSH ranging from
0.025 - 10.0 mU/ml (n = 3). Their response to this was measured using 
MTT.
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2.9 Assessment of Cellular Growth using ^H-thymidine
2.9.1 Labelled Thymidine
Tritiated thymidine is commonly used to detect changes in cell 
proliferation. It is a low energy p emitter which is less expensive and has 
a longer half life than other labelled equivalents. Tritiated thymidine is 
incorporated into replicating DNA, the amount of ^ H-thymidine taken up 
correlating well with the number of cells in the S-phase of the cell cycle 
(Sigal 1985). The use of ^ H-thymidine however does not always reflect 
true growth as will be discussed later.
2.9.2 Materials and Equipment
Packard/Direct beta counter (Packard Instrument company CT USA).
Gas 98.7 % Helium 1.3 % Butane pressure 15 psi 
Self aligning glass fibre filter mats (Packard)
Microwave oven
‘Cold’ stock thymidine 5mM (Sigma)
Stock ^H-thymidine solution (Amersham Int., Pic, UK)
‘O’H Media+0.1 %BSA 
Laminar flow cabinet
Microtitre plates, flat bottomed (Nunc, Roskilde, Denmark)
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Working ^H-thymidine solution was made as follows
0.1 mis of cold thymidine, (final concentration 50 mM) and 0.5 mis stock 
radiolabelled thymidine solution (final concentration 50 pCi/ml), were 
added to 9.4 mis of ‘O’H media containing 0.1 % BSA.
2.9.3 ^H-thymidine Incorporation Method
FRTL5 cells were grown according to the method for assessment of 
cellular growth using MTT (section 2.8.3). After 24 hours incubation 
with selected stimulators, 20 pi of the working ^H-thymidine solution 
was added (the equivalent of 1 pCi per well) and plates were incubated 
for a further 24 hours at 37°C Finally the adherent FRTL5 cells were 
removed from wells by the addition of 50 pi CTC mixture and incubated 
for 20 minutes at 37°C. Cells were then checked microscopically to 
ensure that they had lifted off. The plates were harvested and ^H- 
thymidine uptake measured using the Packard/Direct beta counter 
(Packard/Canberra, Berks., England).
2.9.4 Cel! Harvesting
Radiolabelled cells are suctioned from microtitre wells and are deposited 
in clearly defined discs onto a glass fibre filter mat. The unbound 
thymidine passes through to the reservoir. Advantages of this method of 
harvesting cells are that multiples of 96 samples can be rapidly processed.
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samples are recoverable and the hazards of using liquid scintillant are 
removed, although the hazards of using radiolabelled ^H-thymidine itself 
remain.
2.9.5 Counting
The filter mats are counted using a Direct Beta Counter which uses a 
tritium sensitive avalanche gas ionisation detector (Packard/Canberra).
2.9.6 Method Development
Preliminary experiments were carried out to establish optimum IgG, 
FRTL5 cell concentration and dose response to TSH, using ^H-thymidine 
incorporation as a measure of cell proliferation.
An experiment which combined 4 FRTL5 concentrations ranging from 1 
X 10"^  - 1 X 10^  and 3 concentrations of IgG from 50 - 200 pg/ml was 
carried out. Results are shown in figure 2.10. The FRTL5 cell 
concentration of 5 x 10 !^m\ was chosen as was 100 pg/ml IgG 
concentration as these gave the maximum signal. Using the same 
concentration of IgG as had been used in the MTT assay avoided 
different sample dilutions for different assays. Further experiments 
carried out would use these concentrations.
With the optimum FRTL5 cell concentration now established it was 
possible to check dose response to TSH. Dilutions of bovine TSH which 
covered a range from 0 - 2.0 mU/ml were added to cultures at the stage of
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sample addition i.e., 24 hours prior to pulsing with ^H-thymidine. This 
response is shown in figure 2.11. It was now possible to analyse the 
samples fi"om the three groups now that optimum growing conditions had 
been established.
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Figure 2.10 Optimum IgG and FRTL5 Cell Concentrations Using 
^H-thymidine
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Determination of the combined optimum IgG and FRTL5 cell 
concentrations was carried out using four dilutions of FRTL5 cells which 
ranged from 1 x lO"^  - 1 x 10 /^ml and IgG ranging from 50 - 200 pg/ml 
(n = 3). Measured by the incorporation of ^ H-thymidine.
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Figure 2.11 H-thymidine Dose Response to Bovine TSH
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The response to dilutions of bovine TSH ranging from 0 - 2.0 mU/ml 
(n = 3), using ^H-thymidine to determine cell proliferation.
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2.10 Assessment of Cellular Growth using Cell Proliferation Kit
This is an immunocytochemical system for monitoring cell proliferation 
using a monoclonal antibody to 5-bromo-2’-deoxyuridine (BrdU) to 
detect BrdU incorporated into cellular DNA. Replicating FRTL5 cells 
were exposed to selected thyroid stimulators from the non-toxic goitre 
group and proliferation detected by means of the kit. Statistical 
comparison was made with the normal and disease control groups.
Early work in the kinetics of cellular proliferation was based on the 
mitotic index and the use of agents such as colchicine to measure the flux 
of cells into mitosis (Leblond and Stevens 1948). The S phase was 
described as a discrete interval of DNA synthesis for chromosomal 
replication and was demonstrated by labelling replicating cells with a 
radioactive isotope of phosphorus (Howard and Pelc 1951). After the 
introduction of ^ H-thymidine as a marker for selective labelling in DNA 
synthesis (Taylor et al. 1957), it became easier to study cell kinetics. 
Tritium is a p emitter with a half-life of more than 12 years and therefore 
poses a hazard to users and the environment.
The development of a monoclonal antibody that identifies nuclei 
containing BrdU was an important breakthrough for cell kinetic studies 
(Gratzner 1982). BrdU is one of the halo pyrimidines and like thymidine 
is incorporated into the cellular nuclei at the time of DNA synthesis for 
mitosis (Dolbeare et al. 1983, Morstyn et al. 1983). Provided that the S 
phase cells are able to transport and incorporate sufficient labelled 
precursor to DNA on short term exposure to BrdU, then the BrdU
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labelling index is a measure of the fraction of cells in the S phase 
(Hoshino et al. 1985). The kit provides a chemically defined antibody, a 
highly specific and consistent reagent which does not cross react with 
thymidine.
Five-bromo -2 '-deoxyuridine is incorporated into replicating DNA and is 
localised by means of a specific monoclonal antibody. Cells are 
simultaneously exposed to 5-fluoro-2’-deoxyuridine which inhibits 
thymidilate synthetase increasing BrdU incorporation. Detection of 
bound antibody is achieved using peroxidase conjugated antibody to 
mouse immunoglobulin. Diaminobenzidine (DAB) in the presence of 
cobalt and nickel ions gives blue black staining at sites of BrdU 
incorporation. Care must be exercised with some of the reagents in the 
kit, i.e. inhalation and skin contact should be avoided. BrdU is 
teratogenic and mutagenic and may cause heritable genetic damage. 
DAB is possibly carcinogenic, cobalt chloride is also hazardous and all 
three are harmfiil if inhaled swallowed or absorbed through the skin.
2.10.1 Materials and Equipment
Cell proliferation kit (Amersham Pic )
Petri dishes 50 x 13 mm (Flow Laboratories UK)
Circular glass coverslips No 1 (Lamb UK)
DePeX mounting medium (Lamb UK)
Harris’s Haematoxylin (Sigma)
86
Absolute alcohol (Hayman Ltd)
Hydrogen peroxide (H2O2) 2 % (BDH)
Glacial acetic acid (GCA) (BDH)
20,40, 60, 80 and 100 % methanol (BDH)
6H medium (section 2.8.2)
‘O’H medium + 5 % NCS + P/S glutamine and fungizone (section 2.8.3). 
‘O’H medium + 0.1 % BSA + P/S, glutamine and fungizone (section 
2.8.3)
Normal sheep serum (NSS) from the Scottish Antibody Production Unit 
(SAPU)
PBS 0.0 IM (Oxoid Ltd England)
Phosphate buffer (pH 7.5)
37°C incubator with humidified atmosphere of 5 % C02/air
Humidified incubation chamber e.g. sandwich box lined with damp paper
towel.
Jars for washing and staining.
Cotton wool swabs for drying around specimens after washes.
Microscope 
Wax pen (Dako)
The FRTL5 cells were seeded at a density of 5 x 10^  cells in 6H medium, 
into Petri dishes 3mls/dish and three sterile glass coverslips placed in 
each dish. After incubation at 37°C for 4 days the 6H medium was 
replaced with ‘O’H medium and the cultures incubated for a further 9
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days replacing the media every 72 hours. Samples were added for 48 
hours prior to measuring cell proliferation by means of the kit.
2.10.2 Staining Procedure
1. Sites blocked with 10 % NSS in PBS for 20 minutes.
Wash X 3 with PBS,
2. Apart from 1 control sample, label with BrdU (10 pi + 9.990 mis 
of 6H media) and incubate at 37°C for 60 mins.
Wash X 3 with PBS.
3. Fix in acid/alcohol (95 mis methanol + 5 mis GCA) and incubate 
at room temperature room temp for 30 minutes.
Wash X 3 with PBS.
4. Incubate at room temperature with 2 % in methanol for 20 - 
30 mins.
Wash X 3 with PBS.
5. Incubate with BrdU/nuclease for 60 minutes at 37°C. 
Reconstitute nuclease with 4 mis of distilled H2O and add 40 pi 
of BrdU. The outline of each coverslip is circled with the wax 
pen and covered with 100 pi of reagent.
6. Omitting a second control, incubate with peroxidase anti-mouse 
IgG2a for 30 mins at room temp.
Wash X 3 with PBS.
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7. Stain for 10 minutes with DAB pre-diluted 1/50 with phosphate 
buffer pH 7.5 to which 5 drops of colour intensifier has been 
added.
Wash X 3 with H^O.
8. Dehydrate in 20, 40, 60, 80 and 100 % methanol in ascending 
order.
9. Counterstain for 15 seconds in Harris’s Haematoxylin blue in tap 
H^O for 10 seconds, air dry, mount with DePeX. and coverslip.
2.103 Counting
Slides were looked over to check that staining was uniform and avoiding 
the periphery at least 1000 cells were counted, to determine the average S 
phase fraction. An ocular grid was used and X 40 microscopic 
magnification. Stained cells were counted from right to left, down and 
then left to right etc. The S phase fraction was expressed as the 
percentage of total BrdU labelled cells to the total number of cells 
counted e.g.
S phase fraction = labelled cells x 100
Total cells counted
Of the 2 controls generated during the immunocytochemical procedure 
there should virtually be no positively stained cells.
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2.10.4 Method Development
2.10.4 (a) Choice of Support Medium
There were a few developmental details which had to be worked out 
before commencing.
The FRTL5 cells were grown in 24 well plates, the cells grew well and 
staining with the kit was successful. It would be necessary to change 
from plastic to glass if permanent records of the staining were to be kept 
especially since cell counting is time consuming and tedious, this would 
enable slides to be stored for counting at a later date. Growing the cells 
onto a glass support medium such as a coverslip would then enable them 
to be dehydrated, counter-stained and mounted. It is not possible to use 
plastic with DePeX mounting media as it contains xylene.
The FRTL5 cells were seeded into the 24 well plates each of which 
contained a circular glass coverslip. The coverslips were washed in 
methanol to remove any dust and then autoclaved. Once the 
immunocytochemistry was complete the coverslips were removed, using 
watchmakers forceps, for counter-staining. They were then inverted and 
mounted onto a clean slide using DePex mountant. Great care is required 
as the circular coverslips are fragile. Eventually cells were grown in Petri 
dishes which contained the coverslips making their removal easier.
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2.10.4 (b) Spurious Staining
Non-nuclear staining can result from non-specific binding of antibodies. 
This is preventable by blocking binding sites by pre-incubation with 10 
% NSS in PBS for 20 minutes.
The following table 2.6 shows the results obtained when two different 
samples were stained and demonstrates the difference blocking with NSS 
made.
Table 2.6 Blocking with NSS
NSS blocked sites unblocked sites
Sample 1 Mean No of stained 
cells / 20 fields
38.5 41
Sample 2 86 118
n = 8
Mann Whitney analysis of the data from sample 1 above showed there 
was no significant statistical difference between the blocked and the 
unblocked p = 0.19, mean = 37.9 ± 3.94 (ISD.). Sample 2 did revealed a 
significant statistical difference, p = 0.0009, mean = 86.5 ± 4.69 (1 SD.) 
this result influenced the decision to block with NSS.
The second cause of false positives can be due to endogenous peroxidase 
activity. This is reduced post fixation by incubating for 20 - 30 minutes 
with 2 % hydrogen peroxide in methanol. If the control without label 
contains many positively stained cells, then this step should be included
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in the procedure.
Using the kit (Amersham) and the conditions described in 2.10.2 analysis 
of the 3 different groups from this study were carried out, the results of 
which can be found in chapter 4.
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Chapter Three Quality Control
3.1 Measuring Precision
Measuring the variability within and between both the MTT and 
thymidine methods was carried out as follows. Quality control materials 
were made, stored frozen and used throughout this study, with a 
statistical evaluation of the final results. In the case of the cell 
proliferation kit this type of approach was not feasible owing to the 
increased costs which would be incurred.
The intra-assay variation of a method is an indication of the within batch 
precision of that method. This was measured by analysing the same 
sample several times, within the same assay. The results were expressed 
as the cv. In general the intra-assay variation should be approximately 
half that of the inter-assay variation.
The inter-assay variation reflects the between batch precision of a 
method. This was measured by analysing the same sample over several 
individual assays. Results were expressed as the cv. The 95 % 
confidence interval was calculated (mean ± 2 SD.), within which quality 
control results from further assays would be expected to fall. Any lying 
outwith these limits would result in the repetition of the assay.
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3.1.1 Preliminary Quality Control
This preliminary quality control was carried out using the MTT method 
only.
In order to establish the intra-assay variation of the MTT method the 
following were analysed the specified number of times, within the same 
assay:-
1. ‘O’H + 0.1 % BSA media.
2. ‘O’H + 0.1 % BSA media spiked with bovine TSH giving a final TSH 
concentration of 0.1 mU/ml.
3. ‘O’H + 0.1 % BSA media spiked with bovine TSH to give a final TSH 
concentration of 1.0 mU/ml.
The data are shown in tables 3.1 (a), (b) and (c). The cv. for ‘O’H + 0.1 
% BSA media was quite high at 21 % (n = 32) showing a probable lack 
of precision at this level. The cv’s of the media containing 0.1 and 1.0 
mU/ml TSH were 11.5 % and 12.9 % respectively. The data obtained 
fi’om the measurement of the intra-assay variation at these three levels is 
summarised in figure 3.1.
From the results obtained it was decided that the mean absorbances of 2 
and 3 were too similar to be useful, these were 0.078 and 0.089 
respectively. It was also thought that it would be more appropriate for 
the QC materials to be serum based. This initial work on quality control 
materials led to the development of the materials finally used in 3.1.2.
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Table 3.1 (a) Intra-assay Variation using ‘O’H + 0.1 % BSA Media
Absorbance
0.065
0.041
0.044
0.040
0.045
0.043
0.051
0.057
0.039
0.041
0.063
0.067
0.058
0.058
0.068 n = 32
0.051 mean = 0.04656
0.040 sd = 0.00982
0.044 cv = 21 %
0.049
0.038
0.038
0.039
0.040
0.041
0.041
0.040
0.058
0.041
0.035
0.038
0.039
0.038
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Table 3.1 (b) Intra-assay Variation using 0.1 % mU/ml Bovine TSH
in ‘O’H + 0.1% BSA Media
Absorbance
0.074
0.079
0.094
0.073
0.080
0.077
0.097
0.065
0.070
0.082 n = 23
0.084 mean = 0.07765
0.076 sd = 0.0089
0.076 cv= 11.5 %
0.071
0.066
0.064
0.067
0.078
0.092
0.080
0.086
0.075
0.080
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Table 3.1 (c) Intra-assay Variation using 1.0 mU/ml Bovine TSH 
in‘0 ’H + 0.1% BSA Media
Absorbance
0.075
0.075
0.086
0.082
0.063
0.072
0.094
0.087
0.092
0.083
0.074
0.104
0.103 n = 28
0.099 mean = 0.08896
0.103 sd = 0.0011
0.102 cv = 12.9 %
0.098
0.093
0.094
0.081
0.080
0.085
0.105
0.094
0.081
0.084
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Figure 3.1 MTT Quality Control Summary
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Summary of the intra-assay variation for the MTT method at 3 different 
levels. Mean absorbance was plotted versus TSH concentration.
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3.1.2 Final Quality Control Materials
It was necessary to find biological materials which would give values
similar to those of the study samples.
1. Firstly whole plasma was obtained from the Blood Transfusion 
Service (BTS) at GRI. This was acquired from one donor on whom 
thyroid function tests were normal. Fabriquik, a thrombin preparation 
was added to the plasma (1ml of thrombin per litre of plasma and 
mixed using a magnetic stirrer. Once coagulation had occurred the 
clot was removed and the serum centrifuged to remove any particulate 
material. IgG was prepared from this by the method outlined in 
section 2.4.4 and the total protein content measured (section 2.5.3). 
This was diluted in ‘O’H + 0.1 % BSA to give a final concentration of 
100 pg/ml. Aliquots were stored frozen at -20°C and analysed in the 
MTT and ^H-thymidine proliferation assays. This was designated the 
“low QC” material.
2. Serum was obtained from a patient with Graves’ hyperthyroidism. 
This also had IgG prepared from it and the total protein measured, the 
results obtained from this sample were slightly higher than the low QC 
so it was used in further assays as the “medium QC” material.
3. The third quality control was made by spiking the low QC with bovine 
TSH to a concentration of 5 mU/ml, this was designated the “high 
QC”.
99
The QC materials were aliquoted and stored at -20°C. All three QC’s 
were analysed on each plate in each assay, along with a sample of the 
‘O’H + 0.1 % BSA media in which all samples had been diluted.
3.2 MTT Quality Control Results
3.2.1 MTT Intra-assay Variation
Measurement of the intra-assay variation at three different levels was 
carried out using the low, medium and high QC materials previously 
described in section 3.1.2.
The intra-assay variation of the MTT method was carried out by 
measuring 30 samples of the low QC within the same assay. This data is 
shown in table 3.2 (a). Results are given as means of triplicates, the cv. 
was 4.4 %.
Table 3.2 (b) contains the data obtained from the medium QC, n = 14. 
The cv. was 6.6 %.
The results in table 3.2 (c) show the intra-assay variation using the high 
QC material. The results are presented as means, the cv. was 8.6%.
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Table 3.2 (a) MTT Intra-assay Variation (low QC)
Absorbance
0.113
0.109
0.108
0.110
0.114
0.116
0.112
0.117
0.117
0.116
0.112
0.116
0.115
0.116 n = 30
0.108 mean = 0.113
0.117 SD. = 0.005
0.119 cv. = 4.4 %
0.113
0.120
0.118
0.115
0.112
0.114
0.113
0.112
0.113
0.107
0.111
0.111
0.093
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Table 3.2 (b) MTT Intra-assay Variation (medium QC)
Absorbance
0.149
0.144
0.162
0.166
0.142
0.150 n=  14
0.134 mean = 0.154
0.165 SD. = 0.010
0.148 cv. = 6.6 %
0.154
0.169
0.159
0.162
0.158
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Table 3.2 (c) MTT Intra-assay Variation (high QC)
Absorbance
0.210
0.230
0.240
0.212
0.192
0.237
0.237 n = 16
0.218 mean = 0.229
0.194 SD. = 0.020
0.228 cv. = 8.6 %
0.234
0.261
0.227
0.244
0.250
0.223
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3.2.2 MTT Inter-assay Variation
The precision of the MTT assay was measured using the low, medium 
and high QC materials described in section 3.1.2.
Table 3.3 (a) shows the data obtained from the low QC material which 
was used to evaluate the between assay variation. These results are 
shown in the quality control graph in figure 3.2 (a). The error bars 
indicate the 95 % confidence interval (mean ± 2 SD.).
Similarly tables 3.3 (b and c ) also show the inter-assay variation, using 
the medium and high QC materials respectively. These are shown in the 
corresponding quality control gr^hs in figures 3.2 (b and c) error bars 
also indicate the mean ± 2 SD.
The confidence interval is 95 %. Quality control results lying outwith 
this range resulted in the repetition of the assay.
Table 3.3 (a) MTT Inter-assay Variation (low QC)
Absorbance
0.120
0.124 n = 7
0.141 mean = 0.119
0.124 SD. = 0.014
0.114 cv. = 11.5 %
0.095 ci. = 0.092 - 0.147
0.118
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Table 3.3 (b) MTT Inter-assay Variation (medium QC)
Absorbance
0.171
0.163 n = 8
0.197 mean = 0.168
0.212 SD. = 0.025
0.146 cv. = 15.1 %
0.139 ci. = 0.117-0.219
0.166
0.149
Table 3.3 (c) MTT Inter-assay Variation (1
Absorbance
0.273
0.251
0.275 n = 9
0.305 mean = 0.262
0.240 SD. = 0.027
0.232 cv. = 10.3 %
0.256 ci. = 0.208-0.316
0.297
0.231
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Figure 3.2 (a) MTT Inter-assay Variation (low QC)
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This graph shows the inter-assay variation using the low QC. The error 
bars indicate the mean ± 2 SD, Numbers 1 - 7  refer to the results 
obtained on each of the 7 different occasions on which the assay was 
performed.
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Figure 3.2 (b) MTT Inter-assay Variation (medium QC)
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Quality control graph demonstrating the inter-assay variation of the 
medium QC. The error bars show the mean ± 2 SD. Again, the numbers 
along X axis refer to the number of different occasions on which the assay 
was performed.
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Figure 3.2 (c) MTT Inter-assay Variation (high QC)
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Quality control graph showing the between assay variation using the high 
quality control material. The error bars indicate the mean ± 2 SD. 
Numbers 1 - 9  indicate the number of different occasions on which the 
assay was performed.
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3.3 H-thymidine Intra-assay Variation
Table 3.4 (a) shows the data, in counts per minute (CPM), used to 
calculate the within batch variation. The low QC was measured within 
the same assay the specified number of times (n = 14). The cv. at this 
level was 18 %.
The medium QC data is shown in table 3.4 (b). The sample number was 
10 and the calculated cv. was 17 %.
Table 3.4 (c) also shows data used to calculate the intra-assay variation 
using the high QC. The error at this higher level is indicated by the cv. 
which was 21 %.
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Table 3.4 (a) ^H-thymidine Intra-assay Variation (low QC)
CPM
3034
2304
2902
3194
2365
2049 n = 14
2845 mean = 2789
1976 SD. = 509
3538 cv. = 18 %
3286
3261
3321
2548
2422
Table 3.4 (b) ^H-thymidine Intra-assay Varii
CPM
35327
23310
35193 n = 10
31030 mean = 33573
29423 SD. = 5712
41311 cv. = 17 %
29351
31459
40784
38545
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Table 3.4 (c) ^H-thymidlne Intra-assay Variation (high QC)
CPM
66685
98268
98200
85147
124000
85502
72651
98214
96053
84881
83442
93466
117000
85010
79720 n = 31
95925 mean= 101558
141000 SIX = 21299
107000 cv. = 21 %
90677
132000
119000
128000
107000
146000
133000
122000
110000
65382
105000
92295
85791
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3.3.1 Inter-assay Variation
The data in table 3.5 (a) were obtained using the low QC (section 3.1.2) 
and demonstrates the between assay variation. These results are shown in 
the quality control graph figure 3.3 (a) The cv. was 50 %, error bars 
indicate the mean ± 2SD.
Tables 3.5 (b and c ) show the data obtained using the medium and high 
QC. The inter-assay variation was poor for the medium QC cv. = 83 % 
and that for the high QC better at 22 %. The corresponding QC graphs 
are shown in figures 3.3 (b and c ). The error bars indicate the mean ± 
2SD.
Table 3.5 (a) ^H-thymidine Inter-assay Variation (low QC)
CPM
4371
8359
5808
3749 n = 10
3271 mean = 5133
2152 SD. = 2559
9812 cv. = 50 %
7226
3545
3034
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Table 3.5 (b) H-thymidine Inter-assay Variation (medium QC)
CPM
41706
14396 n = 6
15140 mean = 16446
2379 SD. = 13595
7450 cv. = 83 %
17605
The cv. for the medium QC was unacceptably high , however this QC 
was assayed on the same plate alongside the low and the high QC which 
were within the 95 % confidence interval. In explanation, there may have 
been a problem with the sample or perhaps the precision was just bad at 
this level, the other factor could be the small sample size.
Table 3.5 (c) ^H-thymidine Inter-assay Variation (high QC)
CPM
110500
89597 n = 9
70093 mean = 83883
79000 SD. = 18950
91677 cv. = 22 %
48220
107110
77814
80937
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Figure 33  (a) H-thymidine Inter-assay Variation (low QC)
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Quality control graph showing the between assay variation, of the low 
QC. Error bars indicate the mean ± 2 SD. Numbers 1-10 indicated the 
different occasions on which the assay was performed.
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Figure 33  (b) H-thymidine Inter-assay Variation (medium QC)
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Quality control graph of the medium QC indicating the between assay 
variation. The error bars show the mean ± 2 SD. The numbering 1 - 6  
refers to the number of different times the assay was performed.
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Figure 33  (c) H-thymidine Inter-assay Variation (high QC)
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Quality control graph demonstrating the inter-assay variation of the high 
QC. The error bars show the mean ± 2SD. The numbering 1 - 9  
indicates the different occasions on which the assay was performed.
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3.4 Total Protein Quality Control
3.4.1 Total Protein Intra-assay Variation
Table 3.6 shows the data obtained when 26 samples of BSA 
concentration 600 pg/ml (section 2.5.2) were analysed consecutively. 
This data was used to calculate the within batch precision of the method, 
the cv. for which was 6.5 %.
Table 3.6 Total Protein Intra-assay Variation
Total protein concentration pg/ml
665
685
685
670
770
580
615
685
620
630
630
645 n = 26
700 mean = 662.7
675 SD. = 42.88
705 cv. = 6.5 %
680
660
615
650
640
650
760
640
700
645
630
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3.4.2 Total Protein Inter-assay Variation
Table 3.7 shows the data obtained when a sample of BSA (600 pg/ml ) 
was analysed in 17 individual assays. Figure 3.4 is a quality control 
graph of this data, error bars denote the 95 % confidence interval. The 
cv. was 6.9 %.
Table 3.7 Total Protein Inter-assay variation
Total protein concentration (pg/ml)
670
650
630
645
655
655
660 n = 17
560 mean = 624
530 SD. = 42.9
600 cv. = 6.9 %
600
670
660
560
650
615
600
118
Figure 3.4 Total Protein Inter-assay Variation
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BSA diluted to give a concentration of 600 |ig/ml was analysed in 17 
different assays. These results were used to calculated the inter-assay 
variation. The cv. was 6.9 %. Error bars indicate the 95 % confidence 
interval.
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Chapter Four Results
4.1 Patient Data
The following groups of subjects were studied with the MTT, ^H-thymidine 
and BrdU assays to detect FRTL5 cell proliferation.
1. Goitre group:-
a) 27 with non-toxic goitre pre treatment; 24 female, 3 male.
b) 20 of the same patients with non-toxic goitre after 6 months treatment 
with thyroxine; 18 female, 2 male.
2. Disease control group; 10 patients with multiple sclerosis; 9 female, 1 
male.
3. 27 normal controls; 24 female, 3 male.
4.1.1 Demographic Characteristics of the Study Group
The study population is shown in table 4.1. Each group was matched for age 
and sex. Age data are presented as means ± ISD. Goitre group pre Tx (la) 
vs MS group (2), p = 0.073; goitre group post Tx (lb) vs MS group (2), p = 
0.037, (comparison of this group now shows a significant age difference this 
was due to 2 of the original MS patients being removed fi*om the study when 
their diagnosis of probable MS was not confirmed); goitre group pre Tx (la)
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vs normal control group (3), p = 0.99; goitre group post Tx (lb) vs normal 
control group (3), p = 0.63; MS group (2) vs normal control group (3), p = 
0.067.
Table 4.1 Demographic Characteristics of Study Group
Group n Age (years) ± ISD. female (n) male (n)
(la) NTG Pre Tx 27 46.6 ±13.2 24 3
(lb) NTG Post Tx 20 48.4 ±13.0 18 2
(2) MS 10 39.7 ± 8.4 9 1
(3) Normal controls 27 46.6 ± 12.4 24 3
Age data were expressed as mean ± ISD.
4.2 Statistical Analysis
All statistical analyses were carried out using Minitab Statistical Software. 
Means of triplicates were calculated and significant statistical differences 
between groups were tested for using the student’s t test. The paired t test 
was used to show differences between the pre and post treatment goitre 
group. Statistical significance indicated where p = <0.05.
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4.3 Goitre Grading
Table 4.2 shows the grade of goitre as determined by the clinician in those 
patients for whom data was available (n = 20). Goitres were described as 
simple, small single nodule, solitary large or multinodular which was sub­
divided 1 - 5  according to the enlargement of the goitre defined in section 
2 .1.1.
Table 4.2 Goitre Grade
Simple goitre small nodule solitary large Multinodular
1 2 3 4 5
n = 20
4.4 Thyroid Function Tests
Thyroid function test results pre and post treatment with thyroxine are shown 
in table 4.3. In the pre treatment group the means of all thyroid function tests 
were normal. In the post treatment group, as expected, serum T4 was 
elevated, comparison of the pre and post treatment serum T4 showed a 
significant difference^ p = 0.0033. There was no significant difference 
between pre and post treatment serum T3 p = 0.28. Comparison of pre and
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post treatment TSH results also showed a significant difference p = 0.017. 
Four of the 19 post treatment TSH results showed detectable TSH levels, 
suggesting incomplete suppression.
Table 43  Thyroid Function Tests
T3 nmol/1 
(preTx)
T3 nmol/1 
(post Tx)
T4 nmol/1 
(pre Tx)
T4 nmol/1 
(post Tx)
TSH mU/ml 
(pre Tx)
TSH mU/ml 
(post Tx)
n 10 5 24 17 25 18
mean 2.21 3.00 106.25 151.9 1.22 0.21
SD 0.697 1.38 43.58 52.2 1.64 0.31
Normal ranges; T4 55 - 144 nmol/1, T3 0.9 - 2.8 nmol/1, TSH <5.0 mU/1
4.5 Thyroid Volumes
Table 4.4 shows median thyroid volumes, measured by ultrasound, of the 
goitre group pre and post treatment n = 11. These are also shown in figure
4.1 with inter-quartile ranges in parenthesis. A paired t test showed no 
statistically significant difference between thyroid volume pre and post Tx p 
= 0.70. Four (36 %) of the 11 on whom ultrasound measurements were 
available, had decreases in thyroid volume ranging fi"om 2 1 - 5 1 % .  In a 
further 4 an increase in thyroid volume was seen, these increases ranged 
fi"om 38 - 44 %. The remaining 3 of the 11 showed no change in thyroid
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volume.
Table 4.4 Thyroid Volumes of Goitre Group
n NTG pre Tx NTG post Tx
median thyroid volume (mis) 11 55.1 65.6
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Figure 4.1 Thyroid Volumes Pre and Post Tx (NTG Group)
(33.9-76.2)
E
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E
O>
(32.6-104.1)
PreTx PostTx
Thyroid volumes of the NTG group were compared, pre and post treatment 
with thyroxine n = 11. Median thyroid volumes were plotted with ranges in 
parenthesis. Pre and post Tx volumes were compared using a paired students 
t test p = 0.70, showing no statistically significant difference.
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4.6 Antithyroid Antibodies
Table 4.5 shows anti-microsomal and anti-thyroglobulin antibody results for 
the goitre group n = 13. Titres >1/32 for anti-microsomal and >1/100 for 
anti-thyroglobulin indicate the significant presence of these antibodies. There 
was no reference to Hashimoto’s disease in the case notes of the patient with 
the high antibody titres, this patient previously had a right lobectomy.
Table 4.5 Antithyroid Antibodies
Patient Anti-Microsomal Anti-Thyroglobulin
t29 neg neg
t7 neg neg
t9 neg neg
tl2 neg neg
tl4 1/1600 1/2560
t20 1/100 neg
i l l 1/6400 neg
t38 neg neg
t39 1/6,553,600 1/1,638,400
t41 neg neg
t36 neg neg
t47 neg neg
tl7 neg 1/10
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4.7 MTT Study Group Results
IgG from the 3 groups of subjects was used to stimulate growth in quiesced 
FRTL5 cells for 48 hours. Proliferation was demonstrated by an increase in 
absorption using the dye MTT. The data obtained are summarised in table 
4.6.
Table 4.6 MTT Results Summary
NC Goitre pre Tx Goitre post Tx MS
n 27 27 20 10
mean 0.12 0.104 0.118 0.157
median 0.111 0.112 0.134 0.156
SD. 0.03 0.052 0.047 0.027
The following gr^hs were constructed using medians from table 4.6 with 
inter-quartile ranges in parenthesis.
Figure 4.2 (a) compares the results of the normal controls group (3) (n = 27) 
with goitre patients pre and post treatment groups (la) (n = 27) and (lb) (n = 
20), p = 0.17 and 0.91 respectively. These were compared using the 
student’s t test for unpaired data and were found not to differ significantly.
A paired t test on the pre and post Tx groups (la) (n = 20) and (lb) (n = 20) 
showed no significant difference p = 0.25.
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Figure 4.2 (b) shows the comparison of the normal control group (3) (n = 27) 
with the MS group (2) (n = 10) p = 0.002 and was significantly different. 
Similarly when group(la) (n = 27) and (lb) (n = 20) (NTG pre and post Tx) 
were compared with group (2) these were also found to differ significantly 
(la) vs (2), p = 0.0003 and (lb) vs (2), p = 0.0085. Shown in figure 4.2 (c).
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Figure 4J, (a) FRTL5 Cell Proliferation using MTT in NC vs NTG Pre
and Post Tx Groups
(])Üc
(0
-so
COn
<
(0.1-0.15)
0.09-0.150.1-0.15)
NC PreTx PostTx
Exposure of FRTL5 cells to IgG from the normal control group n = 27, NTG 
pre Tx group n = 27 and the NTG post Tx group n = 20, for 48 hours. 
Subsequent proliferation was measured using MTT. Data were presented as 
medians with inter-quartile ranges in parenthesis, statistical significance 
indicated where p = <0.05. Normal control group vs NTG pre Tx group p = 
0.17; normal control group vs NTG post Tx group p = 0.91. Comparison of 
the pre Tx with the post Tx group p = 0.25.
Values used were means of triplicates.
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Figure 4 J  (b) FRTL5 Cell Proliferation using MTT in NC vs MS
Groups
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FRTL5 cells were stimulated with IgG from the normal control group n = 27 
and the MS group n = 10, for 48 hours. Proliferation was measured using 
MTT. The data are presented as medians with inter-quartile ranges. 
Statistical significance expressed as a p value of <0.05. A significant 
difference was demonstrated between these 2 groups p = 0.002.
Values used were means of triplicates.
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Figure 4.2 (c) FRTL5 Cell Proliferation usings MTT in NTG Pre^  and
Post Tr vs MS Group
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IgG from the NTG pre and post Tx and the MS groups, was incubated with
FRTL5 cells for 48 hours. Proliferation was measured using MTT. Data are
presented as medians with inter-quartile ranges. Statistical significance
indicated where p = <0.05. Statistically significant differences were shown
between the goitre group pre and post Tx vs the MS group p = 0.0003 and
0.0085 respectively.
Values used were means of triplicates.
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4.8 H-thymidine Study Group
Data from the incorporation of ^ H-thymidine for each of the study groups are 
sununarised in table 4.7.
Table 4.7 ^H-thymidine Incorporation Results Summary
NC Goitre pre Tx Goitre post Tx MS
n 27 27 20 10
mean 19371 13787 8286 19657
median 13281 4594 5887 11642
SD. 18571 18774 8214 17452
Figure 4.3 (a) shows the proliferation measured by ^H-thymidine uptake into 
quiesced FRTL5 cells when exposed to IgG from the normal control group 
(3) (n = 27) and patients with NTG pre and post treatment groups (la) (n = 
27) and (lb) (n = 20). Data are presented as medians with inter-quartile 
ranges in parenthesis. The student’s t test for unpaired data was used to test 
for differences between the groups. A p value of <0.05 was considered to be 
statistically significant. There was no significant difference between the 
normal control group (3) and the pre Tx group (la), p = 0.28 however the 
post Tx group was significantly different from the NC group (p = 0.009).
The students t test for paired data was used to compare the pre with the post 
Tx groups (la) vs (lb) a p value of 0.30 showed that there was no
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statistically significant difference between these groups.
Comparison of the normal control group (3) (n = 27) with the MS group (2) 
(n = 10) is shown in figure 4.3 (b). The student’s t test for unpaired data 
showed no significant difference between these groups p = 0.97.
There was no significant difference observed also when the pre Tx NTG 
group (la) (n = 27) was compared with the MS group (2) (n = 10) p = 0.39, 
likewise comparison of the post Tx NTG group (lb) (n = 20) with the MS 
group (2) showed no significant difference p = 0.076 [Figure 4.3 (c)].
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Figure 43  (a) ^-thymidine uptake by FRTL5 Cells in NC vs NTG Pre
and PostTx Groups
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(658-12544)
NC PreTx PostTx
Exposure of FRTL5 cells for 48 hours to IgG from the normal control group 
and the NTG group pre and post Tx with thyroxine. Proliferation was 
measured by ^H-thymidine uptake which was added 24 hours into the 
incubation. Data are presented as medians with ranges in parenthesis, 
statistical significance indicated where p = <0.05. Comparison of normal 
controls (n = 27) with NTG pre Tx (n = 27) p = 0.28; normal controls vs 
NTG post Tx (n = 20) p = 0.009; NTG pre Tx vs NTG post TX (n = 20) p = 
0.30.
Values used were means of triplicates.
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Figure 4 J  (b) ^-thymidine uptake by FRTL5 Cells in NC vs MS
Group
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FRTL5 cells were exposed to the IgG from the normal control and from the 
MS patient groups for 48 hours. FRTL5 cell proliferation was measured by 
^H-thymidine incorporation. Data are presented as medians with ranges in 
parenthesis and p = <0.5 indicating statistical significance. Comparison of 
the normal control group (n = 27) with the MS group (n = 10) p = 0.97. 
Values used were means of triplicates.
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Figure 43  (c) ^-thymidine uptake by FRTL5 Cells in NTG Pre and
Post Tx Groups vs MS Group
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Following a 48 hour incubation with IgG from the NTG pre, post Tx and MS 
groups proliferation of FRTL5 cells was assessed following a 24 hour pulse 
with ^H-thymidine. Data are presented as medians, ranges are shown in 
parenthesis. Comparison of the pre Tx group (n = 27) with the MS group (n 
= 10) p = 0.39 and post Tx (n = 20) vs MS (n = 10) p = 0.076.
Values used were means of triplicates.
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4.9 BrdU Incorporation Results
Thyroid stimulators from groups (la) NTG pre Tx, (lb) NTG post treatment 
and group (3) the normal controls were added to quiesced FRTL5 cell coated 
glass coverslips, after 48 hours the immunocytochemistry was proceeded 
with using the kits from Amersham. Owing to technical difficulties the 
numbers are slightly reduced. A summary of the data showing the S phase 
fractions is shown in table 4.8.
Table 4.8 BrdU Incorporation Results Summary
NC Goitre pre Tx Goitre post Tx MS
n 19 19 18 9
mean 8.37 8.13 9.57 3.49
median 6.1 7.5 9.1 3.9
SD 6.37 8.33 6.09 1.65
Figures 4.4 (a) - 4.4 (c) were constructed using medians from this data, with 
inter-quartile ranges in parenthesis.
Unpaired data was compared using the students two sample t test. No 
significant statistical differences could be demonstrated, firstly between 
group (3) normal controls (n = 19) and the pre treatment group (1 a) (n = 19) 
p = 0.47, group (3) normal controls (n = 19) vs the post treatment group ( lb)  
(n = 19) p = 0.56 and finally using the students t test for paired data between
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the pre and post goitre group ( l a  and b) (n = 18) p = 0.61. Results are 
shown in figure 4.4 (a).
Figure 4.4 (b) shows the comparison between the NC group (3) (n = 19) and 
MS group (2) (n = 9). These groups were significantly different p = 0.0049 
Figure 4.4 (c) compares the MS with the goitre group pre and post TX, p 
values were as follows p = 0.0032 and 0.007 respectively, also indicating a 
significant statistical difference, between these groups.
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Figure 4.4 (a) BrdU Incorporation into FRTL5' Cells in NC vs NTG Pre
and PostTX  ^Groups
(5.8-11.4)
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BrdU incorporation, into FRTL5 ceils treated with IgG from the above 
groups, was measured using the kits from Amersham. Data are presented as 
the median number of cells in the S phase (% stained cells) with ranges in 
parenthesis. NC (n = 19) vs NTG pre Tx (n = 19) p = 0.47, NC (n = 19) vs 
NTG post Tx (n = 19) p = 0.56. The paired t test was used to test for 
statistical differences between the goitre group pre (n = 18) and post Tx (n =
18), p = 0.61.
Values used were means of triplicates.
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Figure 4.4 (b) BrdU Incorporation into FRTL5 Cells in NC vs MS
Group
cu
Ü
T 3
CUc
iSCO
(3.2-11.4)
2.2-5.0)
NC MS
Possible stimulation of FRTL5 cells by IgG from the normal control and the 
MS groups was measured by the incorporation of BrdU, using an 
immunocytochemical kit Data are presented as medians, ranges in 
parenthesis. A t test for unpaired data was used to test for a significant 
statistical difference between these two groups NC (n = 19) vs MS (n = 9) p 
= 0.0049, which was significant.
Values used were means of triplicates.
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F%urc 4.4 (c) BrdU Incorporation into FRTL5 Cells in NTG, Pre and
Post Tx Groups vs MS Group
10 -1
(5.8-11.4)
Ü
Ç
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3.2-14.0
(2.2-5.0)
PreTx PostTx MS
An immunocytochemical system was used to measure proliferation in 
FRTL5 cells previously treated with IgG from the MS and goitre groups pre 
and post Tx. Statistical analysis using the students t test for unpaired data 
showed a significant difference between these groups, NTG pre Tx (n = 19) 
vs MS (n = 9) p = 0.0032, and NTG post Tx (n = 18) vs MS (n = 9) p = 
0.007. Values used were means of triplicates.
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Chapter Five Final Discussion
5.1 T4 Therapy
Treatment of endemic and sporadic goitre with thyroxine is the standard 
textbook therapy (De Groot and Stanbury 1975). It is based upon the idea 
that TSH is the main growth stimulator for thyroid cells (Studer and Greer 
1965, Greer et al. 1967).
We undertook to investigate this in a small study on the group of patients 
with non-toxic goitre (described earlier). Difficulties were experienced 
regarding compliance, for ultrasound scans, follow up appointments and to a 
lesser extent with medication. It was disappointing that only 11/20 attended 
for both thyroid ultrasound scans. Of these 11 patients there was a slight 
increase in mean thyroid volume in goitre group post treatment which did not 
differ significantly fi'om the pre treatment group (p = 0.70). By clinical 
assessment 13/20 of the goitre group had no change in goitre size after 6 
months treatment with thyroxine, the remaining 7 were unrecorded.
The lack of response to thyroxine therapy by both ultrasound and clinical 
assessment was disappointing. Reasons for this may be that a 6 month 
course of treatment was insufficient. Also the goitre population of this study 
was mixed, the majority were multinodular (-80 %), results fi-om other 
studies indicate that a multinodular group would be the least likely to 
respond to treatment with thyroxine (Rojeski and Gharib 1985, Clark 1989,
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Studer and Gerber 1991, Edmonds 1992, Ridgeway 1992).
Several studies on solitary benign nodules gave results ranging from no 
effect (Gharib et al. 1987, Cheung et al. 1989, Morita et al. 1989, Reverter et 
al. 1991, Papini et al. 1993) to >50 % Celani et al. 1990. No effect were in 
the majority but these studies did not include a precisely defined group. In 
1990 Berghout et al. carried out a placebo controlled study of which 68 % 
had MNG, of these 63 % showed a mean decrease of 25 % and the group as 
a whole showed a mean decrease of 15 % with a return to pre treatment 
volume after a few months. In 1991 Reverter’s was placebo controlled on 
solitary benign nodules but showed no appreciable change in thyroid volume, 
here the mean period of follow up was 8 - 1 2  months and all were fully 
suppressed.
A recent 5 year randomised trial using thyroxine for the treatment of benign 
cold nodules concludes that long term thyroxine therapy in the goitre group 
was effective in preventing new lesions and increases in nodule and thyroid 
volume. There was also a significant increase in thyroid size in the control 
group after 5 years (Papini et al. 1998). In conclusion, our finding that 6 
months treatment with sodium thyroxine for NTG had no effect on goitre 
size, this compares with many other studies.
Disadvantages in treating with thyroxine include a risk of sub-clinical 
hyperthyroidism with prolonged therapy (Nygaard et al. 1996), there is also 
an increased loss of bone mass with its associated risks (Faber and Galloe 
1994). Although even this claim is disputed suggesting that sodium
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thyroxine administered at between 50 and 200 pg/day does not affect bone 
turnover and bone mineral density in pre and post menopausal women with 
NTG (De Rosa et al. 1995).
In the expectation that, in patients for whom thyroid volume had decreased 
after ther^y, there would be a decrease in the presence of TGI and 
conversely for those whose thyroid volume increased, results were 
scrutinised, however there was no obvious pattern. It must therefore be 
concluded that it was not possible to predict those patients who would show 
a change in thyroid volume on the basis of TGI values.
5.2 Immunoglobulin Preparation
Criticisms have been made of many of the methods for IgG preparation. 
Ammonium sulphate precipitation yields a crude preparation of IgG and 
requires extensive dialysis of the end product, making it labour intensive. 
Protein A-Sepharose; Protein A is a polypeptide isolated from 
st^hylococcus aureas, yielding pure IgG but is more expensive and when 
many samples are to be purified it is a time consuming process.
The question of contamination has been addressed by Gartner et al. (1987) 
who proposed that contamination o f immunoglobulin preparations with 
EGF was responsible for the increase in proliferation seen in sporadic goitre 
and even Graves’ disease. IgG preparations made by ammonium sulphate 
precipitation were found to have the greatest contamination, with EGF
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concentrations ~ twice that of the serum. When these samples were further 
purified on protein A-sepharose growth promoting activity could not be 
demonstrated. In the serum EGF was elevated in the sporadic goitre group in 
13/23, in the group with Graves’ disease 6/19 and in only 3/17 of the normal 
group. Although there is still the possibility that serum EGF is itself 
involved in goitre growth.
The method used in this study, Sephacryl 200-S, was chosen as it yields IgG 
more economically in expense and labour. In retrospect isolation of IgG 
using protein A-sepharose in terms of purity would have been the more 
logical choice, thus avoiding contamination by other serum proteins or 
growth factors which may have contributed to the growth stimulation of the 
FRTL5 cells.
53 TGI
Methods used to detect thyroid growth immunoglobulins have included ^H- 
thymidine incorporation, the Feulgen histochemical assay and the 
cytochemical bioassay (CBA). The metaphase index assay (MIA) has also 
been developed as a screening assay for TGI (Ealey et al. 1988a). Reputedly 
the most sensitive of these methods is the CBA. The bioassay system ESTA 
(eluted stain assay) was derived from the CBA but is based on cultured cells 
rather than tissue segments (Ealey et al. 1988b) In the literature none have 
escaped criticism.
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In choosing the methods for comparison in this study cost and reproducibility 
were considered. ^H-thymidine and MTT consumable’s were relatively 
inexpensive, equipment for both were available in our department. The 
BrdU kit was the most expensive costing £350 and providing 100 tests per 
kit. The MTT method was technically the least demanding followed by ^H- 
thymidine, the BrdU kit however is very labour intensive. Although with the 
MTT assay it is important to monitor the cell culture environment as 
artefacts can be introduced into the system (Marshall et al. 1995). Design of 
the kit has to be criticised, as once the nuclease reagent (section 2.11.2) is 
reconstituted it cannot be stored, rendering it necessary to process 30 
samples. Processing a batch of 15 samples was considered a more 
manageable number. However the high specificity provided by the kit gives 
it an advantage over the other 2 methods. Many labs have ‘in house’ 
methods using BrdU which would be less expensive and could be tailored 
better to ones requirements.
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5.4 MTT Results
Table 5.1 summarises the results obtained for the subject groups using the 
MTT method.
Table 5.1 Statistical Summary of MTT Results
NC (27) vs. Goitre pre Tx (27) p = 0.17
NC (27) vs Goitre post Tx (20) p = 0.91
Goitre pre Tx (20) vs. Goitre post Tx (20) p = 0.25 
MS (10) vs. Goitre pre Tx (27) p = 0.0003*
MS (10) vs Goitre post Tx (20) p = 0.0085*
NC (27) vs. MS (10) p = 0.0020*
asterisks denote statistical significance.
No significant differences were observed between groups with the exception 
of the MS group, which surprisingly showed evidence of thyroid growth 
immunoglobulins. With such a small sample number (10), confirmation of 
this finding could only come fi'om a larger study. We are unaware of any 
published support for this finding, Strakosch et al. (1978) measured thyroid 
stimulating antibodies in a small group of patients with a variety of 
autoimmune disorders, which included rheumatoid arthritis, pernicious 
anaemia, myasthenia gravis, polymyositis and systemic lupus erythematosis 
(SLE). These were not found to differ significantly fi'om the control group. 
It is well documented that the sera and spinal fluid of MS patients contains
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increased numbers of a variety of antibodies for example anti-nuclear 
antibodies although they do fluctuate (Fukazawa et al. 1997). Also anti­
myelin basic protein antibodies, measles antibodies (Adams and Imagawa 
1962) and canine distemper virus-specific antibodies (Rohowsky-Kochan et 
al. 1995), there is also almost 100 % Epstein Barr virus seropositivity among 
patients with MS. More significant perhaps and linking MS with thyroid 
disease, was a Norwegian study where it was found that MS patients showed 
a significant increased fi-equency in coexistence with rheumatoid arthritis, 
psoriasis and goitre patients (Midgard et al. 1996). Patients receiving 
interferon treatment for MS have shown increases in anti-microsomal and 
thyroglobulin antibodies. Also one of the few studies carried out on organ 
specific antibodies in MS found a significant presence, (16.8 %) of anti- 
microsomal and/or anti-thyroglobulin antibodies compared with 5.9 % of the 
neurological controls the authors support a specific association between 
thyroid autoimmunity and MS (loppoli et al. 1990). Finally patients with 
organ-specific autoimmune disorders are likely to develop antibodies to 
other organs, although there is still no agreement as to whether MS is truly 
autoimmune and organ specific, but it is an accepted concept that the 
immune system contributes to the tissue destruction seen in MS (Lucchinetti 
and Rodriguez 1997).
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5.5 ^H-thymidine Results.
Results obtained with the ^H-thymidine method are summarised in table 5.2 
below, no significant statistical differences were seen with the exception of 
the normal control group when compared to the goitre group post Tx with 
thyroxine.
Table 5.2 Statistical Summary of ^ H-thymidine Results
Raw Data Stimulation Index
NC (27) vs. Goitre pre Tx (27) p = 0.28 p = 0.27
NC (27) vs. Goitre post Tx (20) p = 0.009* p = 0.0071*
Goitre pre Tx (20) vs. Goitre post Tx (20) p = 0.30 p = 0.30
MS (10) vs. Goitre pre Tx (27) p = 0.39 p = 0.44
MS (10) vs. Goitre post Tx (20) p = 0.076 p = 0.094
NC (27) vs. MS (10) p = 0.97 p = 0.96
* = statistical significance.
In order to minimise the poor performance and variability within this 
method, samples were analysed in as few batches as possible and results only 
accepted when QC checks were within the limits set. Also it was thought 
that by expressing data as a stimulation index the wide variation in the 
method would be minimised. These results are also given in table 5.2. The 
stimulation index was calculated as follows:-
S.I. = cpm stimulated cells - cpm unstimulated cells 
cpm unstimulated cells
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Finally to investigate whether there was correlation between the 
thymidine and the MTT methods, all the raw data from both methods were 
expressed as a stimulation index and compared directly. Correlation was 
poor (correlation coefficient r = 0.381). The significant difference 
demonstrated between the NC and goitre group post Tx is puzzling. There 
appears to be a decrease in the level of TGI present in the post treatment 
samples, this is what was hoped for after treatment with thyroxine with an 
accompanying decrease in thyroid volume. This finding is suspicious as you 
might have expected the pre Tx samples to have been increased initially 
followed by a reduction in TGI in the post Tx samples. The high variability 
in this method perhaps has a part to play.
5.5.1 Errors Associated with ^H-thymidine Uptake (Maurer 1981)
The incorporation of ^ H-thymidine into DNA is widely used, as a measure of 
DNA synthesis and cell proliferation. Results based on ^H-thymidine 
incorporation however require careful interpretation.
The assumption that the amount of incorporated precursor is proportional to 
the amount of newly synthesised DNA is incorrect as fluctuations in 
intracellular precursor pools entered by a radioactive precursor can reduce or 
stimulate incorporation rates without corresponding changes in the actual 
rate of DNA synthesis (Smets 1969). Radiation effects e.g. mutations, 
chromosome aberrations, DNA strand breaks, growth retardation and cell
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death all effect DNA synthesis (Cleaver et al. 1972).
5.5.2 Impurities
^H-thymidine contains radiochemical impurities which are the result of self 
decomposition. These products are incorporated rapidly into Tetrahymena 
cells and bind to proteins other than DNA and RNA (Wand et al. 1967). 
Using autoradiography extensive cytoplasmic labelling can be demonstrated, 
but not exclusive labelling of the nuclei. This finding was also observed by 
investigating the distribution of free and bound ^H-thymidine in mouse 
intestinal crypt cells after injection of pure and impure ^H-thymidine (Diab 
and Roth 1970).
5.5.3 Factors Relating to the Synthesis of DNA
In mammalian cells the rate of DNA synthesis is not constant and the DNA 
content does not increase linearly nor exponentially with time (Klevecz et al. 
1974). Early replicating DNA with ^H-thymidine incorporation may be 
subsequently catabolised and the nucleotides reutilised. The problem of 
réutilisation can be reduced by a shorter pulse e.g. 4 hours as opposed to 24 
hours. In some epithelial cells ^H-thymidine may be stored for use later 
which results in a delay between the appearance of ^ H-thymidine in the cells 
and its incorporation into DNA (Moffat and Pelc 1966, Potten 1971 and 
1973).
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5.5.4 DNA Repair
Mammalian cells are capable of repairing damaged DNA pieces using the 
known nucleotides including ^H-thymidine (Ho ward-F lander 1973), 
although precise data are lacking as to the normal frequency of DNA repair 
in resting mammalian cells. Repair also occurs in non-proliferating cells 
therefore uptake of ^H-thymidine into DNA repairing cells cannot 
necessarily be correlated with cell division (Harbers 1975). In rat bone 
marrow réutilisation of ^H-thymidine following catabolism of the DNA of 
dead cells meant that 40 - 60 % of the ^H-thymidine found in the blast cell 
was supplied by DNA of the dead bone marrow cells.
The disadvantages by far outweigh the advantages and true proliferation 
should be determined by a simple cell count and compared with ^H- 
thymidine incorporation (Maurer 1981).
5.6 BrdU Incorporation
Of the three methods compared in this study that using BrdU has the highest 
specificity, but was the most technically demanding and expensive of the 
three. A summation of the statistical results is shown in table 5.3.
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Table 5.3 Statistical Summary of BrdU Incorporation Results
NC (19) vs. Goitre pre Tx (19) p = 0.47
NC (19) vs Goitre post Tx (19) p = 0.56
Goitre pre Tx (18) vs. Goitre post Tx (18) p = 0.61 
MS (9) vs. Goitre pre Tx (19) p = 0.0032*
MS (9) vs Goitre post Tx( 19) p = 0.007*
NC (19) vs. MS (9) p = 0.0049*
asterisks indicate statistical significance.
As with the two preceding methods a statistical difference between the pre 
and post treatment groups was not observed and again it was surprising to 
find differences between the MS patients and the other groups. However in 
the case of BrdU incorporation results were the reverse of that found with the 
MTT method, in that sera from MS patients appeared to inhibit proliferation 
in FRTL5 cells. This may have been due to differences in assay technology. 
Confirmation of these results would be required, along with a larger sample 
size to confirm whether or not this is a true finding.
5.7 Future Developments
Since there is disagreement as to the existence of TGI in simple goitre it is 
unlikely that agreement will be reached unless methods used in their 
detection can be refined, standardised and positive samples compared
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between laboratories. In relation to the detection of TGI, lack of uniformity 
in the measurement of TGI is very apparent and criticism has been levelled at 
most methods (Zakarija et al. 1990). Zakarija suggests a simple screening 
index of growth stimulation along with the DNA measurement, which would 
be technically undemanding and eliminate observer bias. There is also 
evidence supporting species differences, if the detection system is using a 
cell line, as growth factors for human cells may not recognise the receptors 
on cells from other species.
Future work would aim at increasing the study numbers and to recruit a 
precisely defined goitre group. In our opinion the MTT method had the most 
potential for further development, it was the most reliable, accurate, 
technically uncomplicated and the least expensive of the 3 methods 
compared.
In the event of an antigen being found in NTG it is unlikely that it could be 
characterised as characterisation of the antigen to thyroid stimulatory 
immunoglobulin (TSI) in patients with Graves’ disease has so far been 
unsuccessful. Attempts have been made using the method that was used to 
identify and characterise the insulin receptor i.e. immunoprécipitation of the 
TSI antigen followed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-Page) and autoradiography (Rapoport et al. 1984). 
This produced a protein MW -320,000 which was preferentially selected by 
TSI containing serum. Results were inconsistent with those other workers 
on the nature of the human thyroid TSH receptor (Kohn et al. 1983).
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In a recent study patients with Graves’ disease were given short-term steroid 
treatment in order to reduce goitre size. The authors were encouraged by 
achieving this in 3/5 patients. Perhaps there are possibilities for NTG (Mori 
etal. 1997).
Experiments have been conducted on a model of the athymic nude mouse 
and although the human is the ideal experimental model there is huge 
potential for this procedure. Both malignant and benign thyroid tissue have 
been successfiilly xenotransplanted for the study of thyroid stimulating 
antibodies (Gerber et al. 1996).
Finally a review on 10 years of published data on T4 suppressive therapy in 
patients with solitary and predominantly solid thyroid nodules concludes that 
T4 therapy fails to shrink most thyroid nodules with only between 10 - 20 % 
responding to this therapy, response to treatment was defined as a decrease 
of 50 % in nodule size or volume (Gharib and Mazzaferri 1998).
In summary
1. There was no evidence of stimulation or suppression of FRTL5 cells in 
vitro, when treated with IgG from the non-toxic goitre group. The disease 
control patients however showed evidence of FRTL5 cell stimulation with 
the MTT method and with the BrdU method suppression. The ^H- 
thymidine method showed evidence of suppression in FRTL5 cell 
proliferation when the NC group was compared to the goitre group post 
treatment.
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2. Treatment with thyroxine had no effect on thyroid volume or non-toxic 
goitre size.
3. There was no change in serum TGI levels in non-toxic goitre patients after 
thyroxine ther^y.
4. Serum TGI levels pre-treatment had no value in predicting which non­
toxic goitre patients would show a reduction in thyroid volume after 
thyroxine therapy.
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